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Abstract: Hereditary spastic paraplegias (HSP) comprise a large, heterogeneous group of 
genetic neurodegenerative disorders. The unifying symptom present among HSP patients is 
lower limb spasticity, which is caused by the degeneration of cortical spinal motor neuron 
(CSMN) axons. Research on various HSP subtypes has identified a number of common cellular 
pathways that are weak points for long projection neurons, particularly CSMNs. The focus of 
this work has been to generate novel cellular models of several HSP subtypes using human 
pluripotent stem cells (hPSCs). Stem cell models were chosen because of their ability to use 
cells that have the same genetic background as patients generate affected neuronal subtypes. 
The most common HSP subtype SPG4, which is caused by dominant mutations in the SPAST 
gene affecting the microtubule-severing enzyme spastin, was first analyzed. This revealed that 
SPG4-derived telencephalic glutamatergic neurons possess a number of abnormalities, 
including axonal swellings, reduced fast axonal transport, and increased microtubule 
stabilization. Treatment with the microtubule targeting drug vinblastine rescued the axonal 
swelling phenotype in neurons with reduced spastin.  Next SPG3A was analyzed using patient-
specific iPSC-derived telencephalic neurons. SPG3A cells with a novel P342S mutation in 
atlastin-1 had reduced endoplasmic reticulum (ER) complexity, and neurons had reduced 
neurite outgrowth and fast axonal transport. Similar to SPG4, vinblastine was able to rescue the 
neurite outgrowth phenotype in SPG3A neurons. Lastly, two rare, autosomal recessive forms of 
HSP, SPG15 and SPG48, which lack spastizin and AP5Z1 expression respectively, were 
examined.  Telencephalic glutamatergic and midbrain dopaminergic neurons showed a number 
of defects, including reduced neurite outgrowth, increased apoptosis, abnormal mitochondrial  
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morphology and membrane potential. Inhibition of mitochondrial fission with the small molecule 
mdivi-1 rescued mitochondrial and neurite outgrowth defects, offering a potential therapeutic 
avenue in the future.  All of these studies emphasize the utility of hPSC-derived neurons to 
study human monogenic disorders and for testing therapeutic compounds. In the future, these 
models will allow further investigation of the mechanisms that cause the degeneration of a 
subset of neurons, which will be valuable not just for HSP, but for other neurodegenerative 
disorders.  
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1. Chapter 1: 
1.1 Introduction 
 
Hereditary spastic paraplegias (HSP) are a heterogeneous group of genetic disorders that 
result in progressive lower limb spasticity. The symptoms are caused by a length-dependent 
degeneration of axons, most severely affecting corticospinal motor neurons (CSMNs) and those 
of the dorsal columns. Affected neurons display “dying back” axonopathy, particularly in the 
spinal cord, resulting in lost lower motor neuron innervations which produce lower limb spasticity 
and weakness. Over the past decade much work has succeeded in increasing the 
understanding of the genetic causes of the disorder and the function of the genes involved. To 
date, there have been over 71 different gene loci linked, denoted SPG 1-71, of which over 54 
genes have been shown to lead to HSP when mutated. These studies have provided insight into 
several common pathways whose disruption predominantly affects highly polarized projection 
neurons, revealing weaknesses in these cells due to their impressive morphology. CSMNs, 
which are the main neurons affected in HSP, can have axons that reach up to 1 meter in length, 
with axoplasm making up over 99% of the total cells’ volume in some cases [1]. This striking 
polarity makes these cells sensitive to perturbations to many cellular processes, including 
axonal transport, cytoskeletal dynamics, endoplasmic reticulum morphogenesis, and endocytic 
recycling.  
 
1.1.1 Symptoms 
 Hereditary spastic paraplegia, also called Strumpell-Lorrain disease, was first described 
by the German neurologist Adolph Strumpell in 1883 [2] and later by the French doctor Maurice 
Lorrain in 1888 [3]. HSP is classified as a rare disorder by the Office of Rare Diseases (ORD) of 
the National Institutes of Health, and although the prevalence varies between studies, a similar 
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range of 2 – 9.6 in 100,000 individuals is observed [4, 5]. In the United States it is estimated that 
between 10,000 and 20,000 individuals suffer from one of the HSP subtypes, making it 
comparable to the more well-known neurodegenerative disease amyotrophic lateral sclerosis 
(ALS).  Several methods of categorizing HSP are used. HSP can be classified based on its 
mode of inheritance, with all possible forms, dominant, recessive and X-linked reported [6-8]. 
Historically HSP has been classified into two broad categories based on the presence or 
absence of additional symptoms other than lower limb spasticity and weakness. HSP is 
classified as “pure” when spasticity is the only clinical observation, or “complex” when it 
coincides with other clinical features [9].  Common additional neurological features that 
accompany complex HSP include peripheral neuropathy, cataracts, muscle atrophy, ataxia, 
cognitive impairment, icthyosis, epilepsy, dementia, and thinning of the corpus callosum [10, 
11].  Most forms of complex HSP display autosomal recessive inheritance and therefore very 
few patients exist, making it unclear if the additional deficits are due to HSP or are from multiple 
inherited disorders [11].  An additional classification for HSP depends on the age of onset, with 
early onset forms presenting during infancy and late onset forms becoming noticeable as late as 
the eighth decade. More recently, with the identification of many causative genes, HSP is 
classified based on the particular gene that is affected. These classifications are currently not 
very useful to patients since there are still no treatments available for any forms of HSP, 
however they could help inform a patient of the likelihood of passing on the disorder to the next 
generation. In the future as new therapies emerge, the differences in HSP forms may play a 
more important role in guiding treatment course. In addition, the identification of causative 
genes has provided valuable insight into cellular pathways that are critical for axonal 
maintenance and the vulnerabilities displayed by the most morphologically impressive cells in 
the human body.  
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 All forms of HSP display an insidious onset that can take many years before symptoms 
become obvious. Interestingly, when symptoms begin in early childhood, after the initial onset of 
spastic gait or toe walking, the progression usually levels off and does not worsen or improve 
during the duration of the patient’s life [10]. This is quite different than the disease course for 
patients with onset after the age of 6, where the gait deficits usually become progressively 
worse over many years and most will lose the ability to walk later in life [10, 12]. Muscle 
spasticity is more evident in the quadriceps, hamstrings and ankles due to hypertonicity. Often 
the lower limb spasticity is more severe than muscle weakness, which is exemplified in 
wheelchair bound patients who display normal individual muscle strength [12]. Common 
features other than lower limb spasticity include hyperreflexia, and subsets of patients display 
sensory deficits, mainly decreased vibration sensitivity around the ankles [10]. Urinary urgency 
is also frequently associated with both pure and complex HSP. The upper limbs of HSP patients 
generally do not display spasticity, but may show hyperreflexia [6]. This suggests that the 
longest axons are preferentially affected in HSP. 
 
1.1.2 Neuropathology in HSP 
 Most postmortem studies have focused on pure HSP, and the major observation was 
distal axon degeneration of the longest descending motor fibers, mainly the corticospinal tract 
[13]. The most affected region was the thoracic spinal cord where, depending on the patient’s 
height, these axons can reach up to 1 meter in length. Some axons in the longest ascending 
fibers, the fasciculus gracilis tract, also display degeneration, although to a lesser degree than 
the corticospinal tract, which may explain the sensory deficits found in some patients [14].  
Demyelination was observed in regions of axon degeneration, but it is generally believed that 
this is a secondary effect that follows axonal problems for most forms of HSP. Thinning of the 
thoracic spinal cord can be observed in HSP patients by MRI [15].  While there is significant 
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axon loss, neuron death is not easily detected in HSP patients, although there are some reports 
of decreased Betz cells (pyramidal neurons).  
1.1.3 Prognosis and Treatments 
 Although HSP can cause significant long term disability for affected individuals, it is not 
believed to alter the lifespan of those individuals. Currently no therapies exist that can prevent, 
slow the progression, or cure HSP. Most therapies are aimed at alleviating muscle spasticity 
and urinary urgency in affected patients. Muscle spasticity treatments, which aim to maintain 
muscle functionality and prevent contractures, include the GABAB receptor agonist baclofen, 
and the muscle relaxants tixanidine or dantrolene [16]. Intrathecal botulimun toxin injection is 
occasionally used for more severe cases [17]. Urinary urgency is generally well controlled 
through treatment from drugs such as oxybutyinin [10]. Orthotic devises are often used to help 
patients walk with more stability, and supportive devices such as canes or wheelchairs may be 
required as the disease progresses. Physical therapy is recommended for all HSP patients to 
help preserve muscle strength and flexibility.  
 
1.1.4 Cellular Pathogenesis 
 Breakthroughs in basic science research into the genetic causes and pathogenic 
mechanisms of HSP have dramatically accelerated in the past decade (Table 1). Work in this 
field has uncovered many cellular processes that are affected by multiple forms of HSP, which 
have greatly aided in the understanding of the importance of axonal maintenance in human 
disease (Fig. 1-1). Through the rest of this review, some highlights of the recent work on HSP 
will be covered, with a focus on the four forms investigated here, SPG4, SPG3A, SPG15, and 
SPG48. Next, background on the common pathways affected between these four HSP subtypes 
will be discussed, followed by an introduction to the model system we employed. 
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Table 1: HSP loci and known genes, divided into functional groups (compiled from OMIM 
and [1, 11, 18]) 
 Inheri
tance 
Locus Protein Clinical features Frequen
cy 
Models 
Endosome and Membrane traffic related 
SPG3A 
(Atlastin-1) 
AD 14q12-
q21 
Atlastin-1 Early-onset pure, slow 
progression HSP 
<10% AD 
HSP 
C. elegans [19], Zebrafish [20], 
drosophila [21, 22], mouse [23], 
iPSC-derived neurons [24] 
SPG4 
(SPAST) 
AD 2p22 Spastin Variable-onset mainly pure 
HSP 
40% of 
AD HSP 
Zebrafish [25, 26], drosophila [27, 
28], mouse [29], iPSC-derived 
neurons [30] 
SPG6 
(NIPA1) 
AD 15q11.2-
q12 
Non-imprinted in 
Prader-
Willi/Angelman 
syndrome region 
protein 1) NIPA1 
Adult-onset pure HSP ~10 
families 
C. elegans [31], drosophila [32] 
SPG8 
(KIAA0196) 
AD 8q24 Strumpellin Adult-onset pure HSP, 
marked spasticity 
<10 
families 
 
 
Drosophila [33], Zebrafish [34]  
SPG10 
(KIF5A) 
AD 12q13 Kinesin family 
member 5A 
Early-onset pure HSP, can 
be complicated with distal 
amyotrophy 
<10 
families 
Drosophila [35], Mouse [35] 
SPG11 
(KIAA1840) 
AR 15q Spatacsin Childhood to early adult 
onset, thin corpus callosum, 
cognitive impairment, 
neuropathy 
Many 
families 
Zebrafish [36, 37], iPSC-derived 
neurons [38] 
SPG12 
(RTN2) 
AD 19q13 Reticulon-2 Early-onset pure HSP <10 
families 
 
SPG15 
(ZFYVE26) 
AR 14q Spastizin Kjellin syndrome: 
adolescent onset, 
pigmented retinopathy, 
cerebellar signs, mental 
retardation 
<10 
families 
 
SPG17 
(BSCL2) 
AD 11q12-
q14 
Seipin Silver syndrome: variable 
onset, distal amyotrophy in 
hands more than in feet 
<20s 
families 
 
SPG18 
(ERLIN2) 
AR 8p11.23 Endoplasmic 
reticulum, 
lipid raft 
associated 
protein 2 
Severe complex HSP, 
psychomotor retardation, 
thin corpus callosum, 
intellectual disability 
5 families  
SPG20 AR 13qq Spartin Troyer syndrome: childhood 
onset, amyotrophy, 
cerebellar signs, 
developmental  delay 
>10 
families 
 
SPG21 
(ACP33) 
AR 15q Maspardin Mast syndrome: early adult 
onset, thin corpus callosum, 
cognitive decline, 
extrapyramidal features, 
cerebellar signs 
>10 
families 
Mouse [39] 
SPG33 
(ZFYVE27) 
AD 10q24.2 Protrudin Uncomplicated HSP 1 family Zebrafish [40] 
SPG30 
(KIF1A) 
AR 2q37.2 KIF1A Adolescent-onset pure HSP, 
sensory neuropathy 
1 family C. elegans [41], Mouse [42] 
SPG31 
(REEP1) 
AD 2p12 Receptor 
expression-
enhancing 
protein 1 
Variable-onset pure HSP 8% of AD 
pure 
HSP 
Mouse [43] 
SPG51 
(AP4E1) 
AR 15q21.2 Adaptor protein 
complex 4 eta 1 
Complicated, microcephaly, 
hypotonia, white matter loss, 
cognitive impairment 
2 families  
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 Inheri
tance 
Locus Protein Clinical features Frequen
cy 
Models 
SPG53 
(VPS37A) 
AR 8p22 Vacuolar protein 
sorting 37A 
Complicated early-onset 
HSP, cognitive impairment, 
impaired vibration sensitivity 
2 families Zebrafish [44] 
SPG58 
(KIF1C) 
AR chr17:49
04143 
Kinesin family 
member 1C 
Complicated and 
uncomplicated, early 
childhood onset, increased 
deep tendon reflexes, white 
matter abnormalities 
2 families  
SPG59 
(USP8) 
AR chr15:50
769124 
Ubiquitin specific 
peptidase 8 
Complicated, early 
childhood onset, increased 
deep tendon reflexes, 
positive clonus 
1 family  
SPG60 
(WDR48) 
AR chr3:391
35498 
WD repeat 
domain 48 
Complicated, early onset, 
Increased patellar and 
absent Achilles tendon 
Reflexes, peripheral 
neuropathy 
1 family  
SPG61(AR
L6IP1)  
AR chr16:18
804609 
ADP-ribosylation 
factor-like 6 
interacting 
protein 1 
Complicated, early onset, 
increased patellar and 
absent Achilles tendon 
reflexes 
1 family  
SPG62 
(ERLIN1) 
AR chr10:10
1914679 
ER lipid raft 
associated 1 
Uncomplicated, early onset, 
increased deep tendon 
reflexes 
1 family  
Mitochondrial  
SPG13 
(HSPDI ) 
AD 2q24-q34 Heat shock 
protein 60 
Adult-onset pure HSP <10 
families 
Mouse [45] 
SPG7 AR 16q Paraplegin Variable onset, cerebellar 
signs, optic atrophy, 
neuropathy 
~30 
families 
Mouse [46] 
Lipid/Myelination  
SPG2 
(PLP1 ) 
X-
linked 
Xq21 Proteolipoprotein 
1 
Quadriplegia, nystagmus, 
mental retardation, seizures 
<100 
familial 
cases 
Mouse [47] 
SPG5 
(CYP7B1) 
AR 8p Cytochrome 
P450-7B1 
Variable-onset pure and 
complicated HSP 
~20 
families 
Mouse [48] 
SPG28 
(DDHD1) 
AR 14q22.1 Phospholipase 
DDHD1 
Early-onset pure HSP 3 families  
SPG35 AR 16q21-
q23 
Fatty acid 2-
hydroxylase 
Childhood onset, intellectual 
decline, seizures 
1 family  
SPG66 
(ARS1) 
AR chr5:149
676845 
Arylsulfatase 
family 
member I 
Complicated, early onset, 
absent deep tendon reflexes 
1 family  
SPG54 
(DDHD2) 
AR chr8:381
03473 
DDHD domain-
containing 
protein 2 
Complicated, early onset, 
intellectual disability 
6 families Drosophila [49] 
SPG67 
(PGAP1) 
AR chr2:197
712670 
Post-GPI 
attachment to 
proteins 1 
Complicated, early onset, 
increased deep tendon 
reflexes, 
1 family  
Axon guidance/synapse related 
SPG1 
(L1CAM ) 
X-
linked 
Xq28 L1 cell adhesion 
molecule 
Mental retardation, 
hypoplasia of corpus 
callosum, adducted thumbs, 
hydrocephalus 
Over 100 
familial 
cases 
C. elegans [50], mouse [46] 
SPG68 
(FLRT1) 
AR chr11:63
885762 
Fibronectin 
leucine rich 
transmembrane 
protein 1 
Complicated, early onset, 
increased deep tendon 
reflexes, patellar clonus, 
peripheral neuropathy 
1 family  
SPG69 
(RAB3GAP
2) 
AR chr1:220
357421 
RAB3 GTPase 
activating protein 
subunit 2 
Complicated, early onset, 
increased deep tendon 
reflexes, positive clonus, 
intellectual disability, 
deafness, cataract 
1 family  
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 Inheri
tance 
Locus Protein Clinical features Frequen
cy 
Models 
Nucleotide metabolism  
SPG63 
(AMPD2) 
AR chr1:110
167989 
Adenosine 
monophosphate 
deaminase 2 
Complicated, early 
childhood onset, increased 
deep tendon reflexes 
1 family  
SPG64 
(ENTPD1) 
AR chr10:97
605168  
Ectonucleoside 
triphosphate 
diphosphohydrol
ase 1 
Complicated, early onset, 
increased deep tendon 
reflexes 
2 families  
SPG65 
(NT5C2) 
AR chr10:10
4899162 
5’-nucleotidase, 
cytosolic II 
Complicated and 
uncomplicated, both early 
and adult onset, increased 
deep tendon reflexes 
5 families  
Miscellaneous  
SPG9 AD 10q23.3-
q24.2 
Unknown Cataracts, motor 
neuropathy, skeletal 
abnormalities, gastro-
oesophageal reflux 
1 family  
SPG14 AR 3q27-q38 Unknown Variable onset, motor 
neuropathy, mental 
retardation 
1 family  
SPG16 X-
linked 
Xq11.2 Unknown HSP with onset in infancy, 
aphasia, sphincter 
disturbance, mental 
retardation 
1 family  
SPG19 AD 9q33-q34 Unknown Adult-onset pure HSP 1 family  
SPG23 AR 1q24-q32 Unknown Lison syndrome: childhood 
onset, pigmentation 
abnormalities, facial and 
skeletal dysmorphism, 
cognitive decline, tremor 
4 families  
SPG24 AR 13q14 Unknown Childhood-onset pure HSP, 
pseudobulbar signs 
1 family  
SPG25 AR 6q23-q23 Unknown Adult onset, cataracts, 
prolapsed intervertebral 
discs 
1 family  
SPG26 AR 12p11.1-
q14 
Unknown Complicated HSP, adult 
onset, neuropathy and distal 
wasting, intellectual 
impairment 
6 families  
SPG27 AR 10q22.1-
q24.1 
Unknown Variable onset, cerebellar 
signs, neuropathy, mental 
retardation, microcephaly 
2 families  
SPG29 AD 1p31-p21 Unknown Early adolescence onset, 
sensorineural deafness, 
hiatus hernia, pes cavus, 
hyperbilirubinaemia 
1 family  
SPG32 AR 14q12-
q21 
Unknown Childhood onset, mental 
retardation, thin corpus 
callosum, pontine 
dysraphism 
1 family  
SPG34 X- 
linked 
(R) 
Xq24-q25 Unknown Pure HSP, late childhood 
onset 
1 family  
SPG36 AD 12q23-
q24 
Unknown Complicated HSP, lower 
limb sensory deficits 
1 family  
SPG37 AD 8p21.1-
q13.3 
Unknown Pure HSP, variable onset, 
hyperreflexia of the upper 
limbs, decreased vibration 
sensitivity 
1 family  
SPG38 AD 4p16-p15 Unknown Distal amyotrophy (Silver 
syndrome) 
1 family  
 8  
 Inheri
tance 
Locus Protein Clinical features Frequen
cy 
Models 
SPG39 AR 19p13 Neuropathy 
target esterase 
Childhood onset, marked 
distal wasting in all four 
limbs 
2 families Drosophila [51], Mouse [52] 
SPG41 AD 11p14.1-
p11.2 
Unknown Pure HSP, urinary urgency, 
adolescent onset 
1 family  
SPG42 
(SLC33A1) 
AD 3q25.31 acetyl-CoA 
transporter 
Early onset 1 family Zebrafish [53] 
SPG43 
(C19orf12) 
AR 19p13.11
-q12 
C19orf12 Associated with amyotrophy 1 family  
SPG44 
(GJC2) 
AR 1q42.13 Gap junction 
protein 12 
Seizures and spasticity 1 family  
SPG45 
(NT5C2) 
AR 10q24.32
-q24.33 
5’-nucleotidase, 
cytosolic II 
Very early onset , mental 
retardation and ocular signs 
1 family  
SPG70 
(MARS) 
AR chr12:57
908741 
Cytosolic 
methionyl-tRNA 
synthetase 
Complicated, early onset, 
increased deep tendon 
reflexes 
1 family Zebrafish [18] 
SPG71 
(ZFR1) 
AR chr5:324
06955 
ZFR Uncomplicated, early onset, 
increased deep tendon 
reflexes, positive clonus, 
thin corpus callosum 
1 family  
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Figure 1-1: Major pathways affected in HSP. Proteins involved in HSP have a wide range of 
cellular functions, however many of them cluster into several common cellular pathways. Those 
examined here are shown in red. Modified from [54].
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1.1.5 SPG4 (Spastin) 
 Mutations to the SPAST (SPG4) gene were found to result in pure autosomal dominant 
HSP in 1999 and are by far the most common form of HSP,  accounting for 40% of all dominant 
HSP cases [55]. The SPAST gene encodes the ubiquitously expressed microtubule-severing 
protein spastin. All types of possible mutations in SPG4 have been identified, with 28% 
missense, 15% nonsense, 26.5% splice-site point, 23% deletions and 7.5% insertion mutations 
[56]. Spastin is a member of the ATPase associated with diverse cellular activities (AAA) family 
that also includes the microtubule-severing protein p60 katanin. AAA ATPase domains use the 
hydrolysis of ATP to drive a conformation change in the protein [57]. In the case of spastin, 
upon binding to microtubules, the AAA ATPase domain tugs on the C terminus of tubulin, 
causing an internal break [58]. Four main isoforms for spastin have been identified from the 17 
exon protein, generated through combinations of alternative splicing, different promoters and 
different translational initiation sites [59, 60]. The two major protein products are the larger, full-
length protein, termed M1 spastin, which is 616 amino acids in length, and the shorter 530 
amino acid M87 protein that lacks 86 amino acids on its N-terminus (Figure. 1-2). Two less 
abundant isoforms exist, which are variations of M1 and M87, that lack exon 4, which would 
encode 32 amino acids [59].  Currently the effects of the presence or absence of this region are 
not understood since the role of these 32 amino acids is unknown.  Interestingly, M87 spastin is 
more abundant in all cell types than M1, although M1 is more abundant in the brain and spinal 
cord compared to other locations [59, 61]. This observation hints at the possibility that M1 
spastin is responsible for HSP development, since mainly the central nervous system is 
affected. More compelling evidence for the role of M1 spastin in HSP is the observation that two 
other HSP causative proteins, atlastin-1 and NA14, interact with a region on the N-terminus of 
spastin, which is only present in the full-length M1 isoform.  In rats, it was found that M1 spastin 
was absent in developing neurons and became more abundant in mature neurons [61]. Of 
particular note was the abundance of M1 spastin in the adult spinal cord, which is the location of 
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degenerating axons in HSP patients. The importance of M1 spastin was recently called into 
question when a report examining SPG4 iPSC-derived neurons found overexpressing either M1 
or M87 spastin could rescue neurite outgrowth defects [62]. This suggests that both M1 and 
M87 spastin are important for neurite outgrowth, but it remains unclear if both isoforms 
contribute equally to axonal maintenance in vivo. 
  
The spastin protein contains four major domains (Figure 1-2) with the characteristic AAA 
ATPase domain located at the far C-terminus portion of the protein, and directly adjacent to this 
domain is a microtubule binding domain (MBD). Both the AAA ATPase and the MBD allow 
spastin to interact with microtubules and generate internal breaks in them. Towards the N-
terminal region of spastin is a hydrophobic region (HR) that is believed to be involved in 
localizing the protein to specific subcellular membranes by interacting with other proteins 
present. Lastly, the microtubule interacting and trafficking (MIT) domain is an additional protein 
interaction domain. Because M87 lacks the first 86 amino acids of full length spastin, it does not 
possess the hydrophobic region, which seems to account for the differences in subcellular 
localization between M1 and M87 [63]. The M87 isoform is mainly a cytosolic protein that is 
important for cytokinesis through recruitment to the midbody between two still connected 
daughter cells after cell division. Here spastin cleaves the microtubules present and allows for 
the completion of abscission [64]. The M1 isoform is usually membrane associated, localizing 
mainly to the endoplasmic reticulum, the early secretory pathway and the early ER-to-Golgi 
intermediate compartment [65]. It is believed that the localization of M1 spastin is due to the 
hydrophobic domain at its N-terminus.  
A number of studies have shown that spastin is capable of severing microtubules in vitro [66]. 
Cell culture studies were originally utilized to determine the function of spastin. When an 
ATPase-defective form of spastin (K388R) was overexpressed in Cos-7 cells, researchers 
noticed that the mutated protein localized with microtubules, suggesting that spastin could 
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interact with microtubules, but without the ability to hydrolyze ATP, could not dissociate from 
them [66]. Also, when wild-type spastin was overexpressed, microtubule disassembly was 
increased, providing the first evidence for the microtubule severing activity of spastin. Based on 
structural studies and comparison to other AAA ATPase proteins, spastin is thought to interact 
with microtubules through its MBD, allowing the AAA ATPase domain to interact with tubulin, 
and ATP hydrolysis provides energy needed for a conformational change that results in the 
destabilization of the microtubule. It has been shown that spastin can be present in both 
monomeric and hexameric form, with the hexamer relying on the N-terminus for assembly [67].  
The large variety of different mutations present in the spastin gene of HSP patients (>250) has 
led to different hypotheses for the mechanism of these mutations. The majority of mutations are 
nonsense, deletions, or splice site mutations, which are believed to reduce the amount of 
spastin present in a cell, causing disease through a haploinsufficiency mechanism [63]. 
Recently, the observation that almost all of the missense mutations appeared in the AAA 
domain suggests the possibility that some of these mutations could function through a dominant 
negative mechanism, since the protein forms oligomers. In 2008, it was shown that at least one 
missense mutation, E442Q, acted in a dominant negative fashion [67]. Using co-localization 
studies, the researchers were able to show that the mutant spastin was able to interact with 
wildtype spastin, and perturb its localization.  
 
Besides the role of spastin in endoplasmic reticulum morphogenesis, new lines of 
evidence suggest that it is involved in axonal transport [61, 68]. This fits with the role spastin 
plays in microtubule severing, as microtubule arrays are present through the entire length of 
axons and provide both structural support and serve as the railways for organelle transport.  
Axonal transport deficits also neatly match the observation that only the longest projection 
neurons are affected, since they would put the largest strain on transport systems to deliver 
cellular contents to the most distal portions of the cell. If proper materials are not delivered to
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Figure 1-2: Spastin isoforms and domains. The N-terminus of the protein contains two 
domains important for protein-protein interactions, the hydrophobic region (HR) and the 
microtubule interacting and targeting (MIT) domains. The C-terminus contains a microtubule 
binding domain (MBD) and an AAA ATPase domain, which allows spastin to interact and sever 
microtubules. Modified from [1]. 
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the distal regions, it could cause a dying back of the axon, which is seen in HSP. Some of the 
best lines of evidence linking spastin and transport come from two different HSP mouse models 
that possess different spastin mutations. The first generated strain had a deletion in spastin that 
resulted in a premature stop codon to study the effects of reduced levels of spastin [29]. These 
mutant mice displayed minor gait alterations compared to wild-type at 22 months. At as early as 
4 months the mutant mice showed defects in axons located in the spinal cord, with axonal 
swellings evident in both ascending and descending tracts. In affected axons of the corticospinal 
tract, dramatic disorganization of cytoskeletal components was observed. These abnormities 
were restricted to axons, and the neuronal cell bodies remained unaffected. By culturing cortical 
neurons from these mice, the researchers found that retrograde axonal transport was impaired. 
This was evident by the observation that the volume of the axon distal to a region of swelling 
was significantly larger than the proximal region of the axon. Both mitochondria and 
peroxisomes accumulated in the distal portion axon swellings, and not in other regions of the 
cell. In a second HSP mouse model from 2009 containing a splice site mutation that is expected 
to generate a premature stop codon, similar abnormalities to the first mouse model were also 
shown [68]. Gait abnormalities and axonal swellings were again present in these mice, but what 
made this study unique was the quantification of both anterograde and retrograde axonal 
transport. To do this, time-lapse microscopy was used to follow labeled mitochondria and APP 
as a marker for membrane bound organelles. Contrary to what was suggested in the first HSP 
mouse model, these researchers found anterograde axonal transport to be diminished, not 
retrograde. Also, swellings appeared to be in random locations along the axon, where in the 
previous mouse model, the swellings were more distally localized. These inconsistencies 
between the two mouse models suggest that different types of mutations could function in 
different ways even if both result in decreased spastin levels, and it remains to be seen if this is 
indeed the case in human neurons.  
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As mentioned earlier, M1 spastin localizes to the early secretory pathway in cells, 
interacting with these membranes through the hydrophobic domain at the N-terminus. The HD is 
predicted to form a hairpin loop capable of inserting itself into the outer leaflet of a lipid bilayer 
through hydrophobic wedging [69]. Three classes of proteins that display hydrophobic wedging 
have also been shown to insert themselves into membranes as a mechanism for generating the 
extreme membrane curvature that is seen in the tubular endoplasmic reticulum, including the 
reticulons, REEPs and atlastins [69]. Interestingly, members of all three classes are associated 
with additional forms of autosomal dominant pure HSP, suggesting a similar mechanism.  
 
1.1.6 SPG3A (Atlastin-1) 
 SPG3A is caused by mutations to the protein atlastin-1 and accounts for approximately 
10% of HSP cases, making it the second most common cause of HSP [70]. Atlastin-1 mutations 
result in early onset pure HSP that displays autosomal dominant inheritance. Because deficits 
are seen at such a young age in SPG3A patients, it has been suggested that this form of HSP is 
neurodevelopmental, while other late onset forms are neurodegenerative.  Atlastin-1 is the 
founding member of a small group of proteins (atlastin1-3) in the superfamily of dynamin-related 
GTPases. It is a 558 amino acid protein that possesses a large GTPase domain at the N-
terminus, followed by a middle domain that serves an unknown function, and two 
transmembrane domains at the C-terminus [71] (Fig. 1-3). Atlastin-1 localizes to the Golgi 
apparatus and also to particular regions of the tubular endoplasmic reticulum network [71, 72].  
The localization of atlastin-1 to the ER is due to the presence of an ER localization signal at the 
C-terminus. Early work into the function of atlastin-1 has relied on in vitro cellular models. In 
2008, a group found that when a mutant or dominant negative atlastin-1 protein was 
overexpressed in HeLa cells, the endoplasmic reticulum was severely affected. Much less 
branching was present in the tubular endoplasmic reticulum, while there was an increase in the 
endoplasmic reticular sheets, associated with the rough ER [71]. This observation, along with  
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Figure 1-3: Atlastin-1 domains. Atlastin-1 consists of three main domains, the large GTPase 
domain, the middle linker domain, and two trans-membrane domains (TMDs). Each TMD 
partially inserts into ER lipid bilayers through hydrophobic wedging. At the C-terminus is a KDEL 
ER retention (ERR) signal.  
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subsequent studies, has led to the prevailing model that implicates atlastin-1 in the formation of 
the smooth endoplasmic reticulum network, which is present throughout the entirety of all cells, 
including axons and dendrites of neurons [73]. The tubular ER is important for lipid and 
cholesterol metabolism and serves as a store for calcium inside of the cell, which is important 
for synaptic transmission and plasticity [73].  The ER is a very dynamic organelle with two main 
subdivisions: the sheets where protein synthesis occurs and the vast network of tubular ER [74]. 
The tubular ER is present throughout the entirety of the cell and moves along microtubule tracts, 
allowing it to localize in even the most distal portions of a neuron’s axon [73]. Atlastin-1 controls 
ER network morphogenesis by driving the fusion of individual ER tubules, allowing the formation 
of three-way junctions.  The reduction of atlastin-1 in rat cortical neurons resulted in decreased 
axonal length and the presence of cells that completely lacked an axon [71]. In vivo studies of 
atlastin-1 function have focused on model organisms such as Drosophila and zebrafish (Danio 
rerio). When the atlastin-1 homologue was knocked-down in zebrafish, researchers observed 
abnormal organization of spinal motor axons which reduced larval movement [20].  These 
abnormalities were credited to alterations in bone morphogenetic protein (BMP) signaling. The 
observation that atlastin-1 can partially localize to endosomes suggested that it may alter 
endocytosis of BMP receptors.  There were no observed abnormalities in ER organization, 
which suggests a potential difference in the function of atlastin-1 between zebrafish and 
mammals, and further studies are needed to clarify these issues.   
 In addition to regulation of ER morphogenesis, atlastin-1 has been shown to regulate 
lipid droplet production. Lipid droplets consist of lipid ester cores that are surrounded by 
phospholipid monolayers and serve as the major fat storage organelles in eukaryotic cells [75]. 
The ER plays an important role in lipid droplet synthesis, as the two organelles are closely 
associated with one another, and lipid droplet growth requires interaction with the ER [76]. The 
role of atlastin family members in lipid droplet regulation was first identified in C. elegans, where 
mutations not only altered ER morphology, but also lipid droplet size [19]. In contrast, 
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overexpression of atlastin increased lipid droplet size. These observations were later confirmed 
in HeLa cells [77]. This work suggests that atlastin-mediated changes to ER morphology affects 
lipid droplet shape. In the future, it will be interesting to determine if alterations to lipid droplet 
size have any pathological consequences in SPG3A patients.  
1.1.7 ER morphogen complex 
In addition to atlastin-1 and spastin, two other HSP-related proteins were found to 
localize to the endoplasmic reticulum. The third most common cause of HSP involves mutations 
to the SPG31 gene, which encodes the receptor expression enhancing protein 1 (REEP1) [69]. 
Humans and other mammals have 6 different REEP family members (REEP1-6), which are 
highly conserved membrane proteins. Through phylogenetic analysis, REEP1 was found to be 
closely related to the DP1/Yop1p proteins that are involved in shaping tubular ER. In fact, 
REEP1 predominantly localized with tubular ER, and similar to what was seen in atlastin-1 
mutant expressing cells, mutant REEP1 expression impaired tubular ER network formation. In 
cultured rat cortical neurons, REEP1 colocalized with both M1 spastin and atlastin-1 through its 
hydrophobic domains. The ER shaping protein reticulon-2 was identified as the causative gene 
in the autosomal dominant SPG12 [78]. Like REEP1, reticulon-2 also is a direct binding partner 
with M1 spastin.  
This determination that four HSP proteins localize to the ER and interact with each other 
has led to the proposal that defects to the so called “ER morphogen complex” are central to the 
pathogenesis of over 60% of HSP [1]. The “ER morphogen complex” describes a complex 
formed by interacting proteins, including atlastin-1, spastin, REEP1 and reticulons, that 
functions to regulate the formation and localization of the endoplasmic reticulum.  Atlastin-1 is 
needed for the formation of the tubule ER network, by regulating the fusion of tubules to form 
three-way junctions. REEP1 and reticulons are critical proteins involved in shaping the ER, and 
can generate the extreme curvature displayed in the tubular ER. Lastly, spastin is involved in 
linking the ER to cell’s cytoskeleton, through microtubule interaction. This is believed to provide 
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structural support for the ER, and also allows transport of the ER throughout the cell. If any of 
these components of the “ER morphogen complex” are mutated, the resulting abnormality in  
ER morphology could negatively affect axons of long motor neurons, leading to loss of synaptic 
connection and lower limb spasticity [1]. 
 
1.1.8 SPG11, SPG15, and SPG48 
Besides the more common autosomal dominant forms of HSP, there is a long list of 
recessive mutations that can lead to complex forms of HSP. SPG11 and SPG15 are the most 
common recessive forms of HSP, and are almost clinically identical [79, 80]. These two forms 
account for 25% of the autosomal recessive subtypes [81]. Both forms present with cognitive 
impairment, dementia, ataxia, and thinning of the corpus callosum, in addition to lower limb 
spasticity. SPG11 and SPG15 encode spatacsin and spastizin respectively, both of which are 
direct binding partners [82, 83]. These two proteins can also bind to the heterotetrameric 
adaptor protein complex 5 (AP5), which is affected in SPG48.  SPG48 is the result of mutations 
to the AP5Z1 gene, which encodes the adaptor protein complex ζ subunit (AP5Z1) [84]. AP5Z1 
is a subunit of the common heterotetrameric adaptor protein complex 5 (AP-5), an evolutionarily 
conserved complex thought to be involved in endosomal dynamics, although its precise 
localization and function are still unclear [85]. Adaptor proteins (APs) are a family of 5 related 
protein complexes, with AP-5 being the most recently discovered [86]. AP-1 and AP-2 are the 
most well-characterized, and have been shown to promote clathrin  assembly in vitro by 
providing a bride between clathrin and membranes [87]. APs are comprised of 5 subunits, β1-5, 
one of either α, γ, δ, ε, or ζ, and μ1-5, and σ1-5 [85]. In addition to AP5Z1, mutations to the AP-
4 subunit AP4E1 were shown in 2011 to result in an autosomal recessive form of HSP, SPG51 
[88]. Another interesting aspect of SPG11, SPG15, and SPG48 is that they can present with 
prominent juvenile parkinsonism, which has shown improvement following dopaminergic 
therapy [62, 89, 90]. It is particularly intriguing that both muscle spasticity, due to cortical spinal 
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motor neuron degeneration, and parkinsonism, caused by dopaminergic defects, occur following 
the loss of one gene. 
Although there is relatively little known about these three proteins, there is evidence that 
they may be involved in axonal outgrowth and targeting in zebrafish [91], autophagy [92-94], 
cytokinesis [95, 96], and potentially in axonal transport [81]. The evidence linking spastizin and 
spatacsin to autophagy is particularly convincing. Through a series of knockdown and 
overexpression experiments, Chang et. al. demonstrated that spastizin and spatacsin are 
required for autophagic lysosome reformation, a process that allows the replenishment of 
lysosomes [93]. Another report showed that spastizin knockdown fibroblasts had an impairment 
of autophagosome maturation and an accumulation of immature autophagosomes [97]. This link 
with autophagy is particularly interesting, since defects in this pathway have been associated 
with other forms of parkinsonism. Kufor-Rakeb syndrome, which has symptoms that are similar 
to SPG15, including pyramidal degeneration and early onset parkinsonism, is caused by loss-of-
function mutations to the gene that encodes the lysosomal protein ATP13A2 (PARK9) [39]. In 
addition, it has been suggested that abnormal accumulation of α-synuclein inhibits the 
lysosomal enzyme glucocerebrosidase, potentially causing Parkinson’s disease [40, 41]. 
Importantly, loss-of-function mutations to the glucocerebrosidase gene results in Gaucher 
disease, which is associated with parkinsonism [42].   
 
1.1.9 HSP Summary 
As the causative genes are identified in the remaining HSP loci, more themes important 
to axonal maintenance besides endoplasmic reticulum morphogeneis, axonal transport, and 
microtubule dynamics are expected to be identified. This review presented the field’s current 
understanding of the three most common causes of HSP, involving proteins that function 
together to form, localize, and maintain the tubular ER network in cells. It has become quite 
clear that proper functioning of the ER is needed not only for the formation and stability of the 
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longest axons in the CNS, but also for preventing disease. Although there are many remaining 
questions for these forms of HSP, based on the current findings, it would appear that long motor 
neurons are a tissue that is most susceptible to misregulation of ER structures. It has been 
suggested that perhaps tubular ER may be necessary at the synapses of these long neurons, 
and when mutant spastin, atlastin-1, REEP1 or reticulon-2 prevent the proper distribution of the 
ER, axonal dying back is the outcome. These subsets of HSP have identified an inherent 
weakness in long projection neurons, and in the future, as the mechanism of other forms of HSP 
are realized, further weaknesses may become evident. In addition, three autosomal recessive 
HSP subtypes associated with juvenile parkinsonism, SPG11, SPG15, and SPG48, were 
discussed. Although there are little data about the function of the proteins involved in these 
subtypes, evidence appears to link them to a role in the endomembrane system and autophagy. 
Although HSP is a rare disorder, studying the mechanisms of this disease may provide 
invaluable insight into the progression of more common disorders that result in axonal 
degeneration, including amyotrophic lateral sclerosis and multiple sclerosis.  
 
1.1.10 Disease-modelling with induced pluripotent stem cells 
Embryonic stem cells (ESC) are pluripotent cells that have two important characteristics. 
First, they have the ability to proliferate indefinitely, and they can generate any cell type in the 
adult body, from all three germ layers. In 1981, the first mouse embryonic stem cells were 
isolated from the inner cell mass of preimplantation blastocysts [98, 99]. These cells could be 
cultured indefinitely, formed multiple cell types in vitro, and could generate teratocarcinomas 
when injected into mice.  Mouse ESCs have proved to be an invaluable tool for studying 
mammalian development, and also led to the generation of the field of gene targeting [100]. In 
1998, the first human embryonic stem cells were generated by Dr. James Thompson [90].  This 
reignited interest in stem cell biology with major implications for regenerative medicine. 
However, ethical issues concerning the destruction of embryos led to the search for additional 
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sources of pluripotent cells. It was known that cells could be reprogrammed back to an earlier 
developmental state since John Gurdon transferred the nucleus of a fully differentiated intestinal 
epithelial cell from Xenopus into oocytes in 1962 [101, 102]. This was the beginning of somatic 
cell nuclear transfer (SCNT), which was successful in mammals as well, when the sheep Dolly 
was generated [103] and later in mice [104].  
As more was understood about the mechanism of pluripotency in mammalian cells, Dr. 
Shinya Yamanaka’s group sought to reprogram mouse somatic cells using defined factors [105].  
In a groundbreaking report, researchers chose to force somatic cells to express various 
combinations of 24 transcription factors that are upregulated in ESCs and found that just 
OCT3/4, KLF4, SOX2 and c-MYC could reprogram cells back to an ESC-like state. The 
generated cells, termed induced pluripotent stem cells (iPSCs), were shown to display many 
similar properties of ESC, including self-renewal and the ability to form cells of all three germ 
layers. A year later, this feat was accomplished in human cells by two independent labs, with 
Yamanaka’s group using the same four factors from the mouse study (Yamanaka’s factors) 
[106], and the Thompson lab showing similar results with OCT3/4, SOX2, LIN28 and NANOG 
(Thompson factors) [107].  Shortly after these reports, some potential benefits became clear to 
the scientific community, including the ability to generate iPSC lines from patients with genetic 
disorders to model diseases, and the reduced risk of immune rejection following transplantation 
of tissues derived from iPSCs that came from the same patient.  
In the past eight years since the first generation of iPSCs, enormous progress has been 
made to increase the efficiency in generating these cells using much safer reprogramming 
methods. An important focus of many groups has been to design reprogramming methodologies 
that are integration free, as numerous reports have shown that integrated transgenes can result 
in increased tumorigenicity and decreased differentiation potential [108].  
 Over the past several decades, a large amount of effort has been directed towards 
developing reproducible directed differentiation protocols that allow the generation of clinically 
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relevant cell populations from pluripotent stem cells [109]. This work has provided researchers 
for the first time with access to large quantities of human neurons, including spinal motor 
neurons [110], midbrain dopaminergic neurons [111, 112], telencephalic glutamatergic neurons 
[113, 114], and medium spiny neurons [115]. The ability to generate defined populations of 
neuronal subtypes fueled the excitement over the ability to replace affected cells in various 
neurodegenerative diseases [116]. While progress towards this ambitious goal has progressed 
slowly, work towards another application for stem cell-derived neurons, “in vitro disease 
modelling”, has rapidly taken off.  The ability to generate patient specific neurons allows 
researchers to examine processes that are not easily observed in postmortem tissues. The 
combination of directed neuronal differentiation and iPSCs has allowed the examination of 
patient-derived neurons that harbor pathogenic mutations. This strategy has successfully 
recapitulated phenotypes from ALS [117, 118], spinal muscular atrophy [119], Huntington’s 
disease [120], Parkinson's disease [121], and Alzheimer’s disease [122]. In addition, the 
examination of ALS iPSC-derived neurons was able to show that a novel therapeutic compound 
was more beneficial than two drugs that recently failed clinical trials [123].  Prior to our work, no 
iPSC-based models of HSP have been reported.  
 Here, we have utilized human iPSCs to generate models of four HSP subtypes, SPG4, 
SPG3A, SPG15, and SPG48. Prior to this work, studies on SPG4 have focused on knocking 
down or overexpressing spastin in cell types not affected in patients, or animal models that do 
not fully recapitulate phenotypes observed in patients. To date, there have been no published 
animal models of SPG3A, SPG15, or SPG48, but valuable information on the role of these HSP 
proteins has been uncovered using engineered cell lines. Because there has been no prior work 
on these four HSP subtypes using human neurons, we used iPSCs to generate models and 
perform pilot drug screening studies. This work is presented here, first with a chapter detailing 
some of the important methods that were used in these studies.
 24  
2. Chapter 2 
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2.1 Summary 
 
Impaired axonal development and degeneration are implicated in many debilitating 
disorders, such as hereditary spastic paraplegia (HSP), amyotrophic lateral sclerosis (ALS), and 
peripheral neuropathy. Human pluripotent stem cells (hPSCs) have provided researchers with 
an excellent resource for modeling human neuropathologic processes including axonal defects 
in vitro. There are a number of steps that are crucial when developing an hPSC-based model of 
a human disease, including generating induced pluripotent stem cells (iPSCs), differentiating 
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those cells to affected cell-types, and identifying disease-relevant phenotypes. Here, we 
describe these steps in detail, focusing on the neurodegenerative disorder HSP. 
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2.2 Introduction 
It became evident shortly after the first successful derivation of human embryonic stem 
cells (hESCs) [90] and iPSCs [106] that these cells would be invaluable for researchers looking 
to study human disorders, particularly diseases affecting the nervous system, where access to 
tissue is limited. Because these cells retain mutations present in patients, they can recapitulate 
many of the phenotypes in neurodegenerative disorders while maintaining the correct human 
genetic background. In addition, developmental biology has progressed at a rate that has 
allowed the directed differentiation of human pluripotent stem cells (hPSCs) to numerous 
distinct cellular populations, including various neuronal subtypes [110, 112, 124-131]. These 
properties of hPSCs make them an ideal system to study neurodegenerative disorders in 
human cells.  
 
In order to generate an accurate model of a neurodegenerative disorder, there are 
several important steps that must occur. The first step is to generate hPSCs that will be used to 
model a disease of interest. This can be accomplished in multiple ways, including generating 
iPSCs from affected patients and controls, or if a disease occurs through a haploinsufficiency 
mechanism, knockdown hESCs can be generated. The latter is useful when access to patient 
tissue limited, or when confirming findings observed in patient-derived iPSCs. Next, the hPSCs 
are differentiated to the cell-type that is affected in patients. In our case, forebrain glutamatergic 
neurons are the main cell-type which are affected in hereditary spastic paraplegia. Confirming 
that a sufficient percentage of the differentiated cells are the correct cell-type and that there is 
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not a dramatic difference between lines is crucial, and must be determined prior to examining 
disease-specific phenotypes. Lastly, once the appropriate neurons are generated, you can 
examine the phenotype of the mutant cells compared to controls. Here, we will focus on two 
common defects observed in axonal degenerative diseases: neurite outgrowth deficits and 
alterations to fast axonal transport of mitochondria.  
 
Impaired axonal functions underlie many neurodegenerative diseases, especially those 
which affect projection neurons. One process that is often affected is axonal transport. 
Projection neurons rely heavily on fast axonal transport to deliver membrane proteins, synaptic 
vesicles, axolemmal components and mitochondria to the distal portions of the cell from the 
soma [132]. A number of additional adult onset neurodegenerative diseases display defects in 
axonal transport, including amyotrophic lateral sclerosis [133], spinal muscular atrophy [134], 
Huntington’s disease [135-137] and Alzheimer’s disease [138-141]. Mutations affecting the plus-
end directed MT-based motor kinesin heavy chain (kinesin family, member 5A), result in a form 
of HSP (SPG10), confirming that perturbations to fast axonal transport can result in axonal 
degeneration [142]. The fact that the majority of protein is generated within the soma, and must 
be transported throughout the axon via anterograde transport makes efficient transport 
particularly critical in neurons [143]. Transport of organelles, including mitochondria, is also 
essential for neurons [144, 145]. Mitochondria move in a saltatory fashion; where some are 
rapidly transported long distances within axons, others appear stationary [146-150]. Kinesin 
proteins mediate transport in the anterograde direction towards the plus-end of microtubules 
[149, 151, 152], while cytoplasmic dyneins mediate transport in the retrograde direction towards 
the minus end of microtubules [149, 153]. The precise regulation of mitochondrial localization is 
necessary for regulating energy demand and preventing cell death [154]. Here we will describe 
how to image and analyze mitochondrial transport in hPSC-derived neurons.   
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2.3 Materials 
2.3.1 Stock Solutions 
1. DMEM (1X): Life Technologies, cat. no. 11965-092. 
2. DMEM/F12 (1X): Life Technologies, cat. no. 11330-032. 
3. Fetal Bovine Serum (FBS): Life Technologies, cat. no. 16000-044. 
4. Knockout Serum Replacer (KOSR): Life Technologies, cat. no. 10828-028. 
5. Neurobasal Medium (1X): Life Technologies, cat. no. 21103-049. 
6. N-2 (100X): Life Technologies, cat. no. 17502-048. 
7. B27 (50X): Life Technologies, cat. no. 17504-044. 
8. Glutamax (100X): Life Technologies, cat. no. 35050-061. 
9. Non-Essential Amino Acids (100X): Life Technologies, cat. no. 11140-050.  
10. Trypsin-EDTA (0.05%): Life Technologies, cat. no. 25300-054. 
11. Phosphate Buffered Saline, pH 7.4 (1X): Life Technologies, cat. no. 10010-023. 
12. StemPro Accutase (1X): Life Technologies, cat. no. A11105-01. 
13. Trypsin Inhibitor (1 mg/mL): Dissolve 50 mg in 50 mL of DMEM F/12, then pass through 
a 0.22 µm Steriflip filter.  
14. FGF2 (100 µg/mL): Dissolve 100 µg into 1 mL of sterile PBS with 0.1% BSA 
(PeproTech, cat. no. 100-18B). 
15. Ascorbic Acid (200 µg/mL): Dissolve 2 mg ascorbic acid in 10 mL PBS. Store at -80°C. 
16. Cyclic AMP (1 mM): Dissolve 4.914 mg cyclic AMP in 10 mL sterilized water. Store at -
80°C.  
17. BDNF, GDNF, IGF1 (100 µg/mL): Dissolve 100 µg of growth factor in 1 mL of sterile 
water.  
18. Mouse Laminin (1 mg/mL): Invitrogen cat. no. 23017-015, aliquot and store at -80°C until 
use. After thawing, store at 4°C.  
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19. MitoTracker CMXRos (50 nM): Dilute 0.5 µL 1 mM stock into 10 mL of NDM medium 
(Life Technologies, cat. no. M-7512).  
2.3.2 Media 
1. MEF Media (1 L): Filter 890 mL DMEM, 100mL FBS, and 10 mL NEAA through a 0.22 
µm filter flask. 
2. hESC Media (1 L): Filter 785 mL DMEM/F12, 200 mL KOSR, 10 mL NEAA, 5 mL 
Glutamax, and 7 µL β-ME through a 0.22 µm filter flask. 
3. Neural Induction Media (NIM, 500 mL): Add 5 mL N2, 5 mL NEAA, and 1 mL of 1 mg/mL 
Heparin to 489 mL of DMEM/F12. Add 1:200 B27, 1:1,000 cAMP, 1:10,000 IGF1 for 
neural differentiation.   
4. Neural Differentiation Media (NDM, 50 mL): Add 0.5 mL N2, 0.5 mL B27, 0.5 mL NEAA,  
to 48.5 mL of neurobasal medium. Prior to use, add 1:1,000 cAMP, 1:1,000 ascorbic 
acid, 1:1,000 laminin, 1:10,000 IGF1, 1:10,000 BDNF, 1:10,000 GDNF.  
 
2.3.3 Transfection Reagents 
1. pCXLE-hOCT3/4-shp53-F: Addgene plasmid 27077. 
2. pCXLE-hSK: Addgene plasmid 27078. 
3. pCXLE-hUL: Addgene plasmid 27080. 
4. pCXLE-EGFP: Addgene plasmid 27082.  
5. NHDF Nucleofector Kit: Lonza, cat. no. VPD-1001. 
2.3.4 Tissue Culture Supplies 
1. 10 mL glass pipettes 
2. 6-well tissue culture treated dishes 
3. T75 non-treated flask 
4. Glass bottom 35 cm dish: MatTek, cat. no. PG35G-1.5-14-C 
2.3.5 Antibodies 
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1. IgM anti-Tra-1-60: Santa Cruz, 1:50, cat. no. sc-21705. 
2. Goat polyclonal IgG anti-Nanog: R&D Systems, 1:500, cat. no. AF1997. 
3. Mouse monoclonal IgG3 anti-SSEA-4: Developmental Studies Hybridoma Bank, 1:100, 
cat. no. MC-813-70. 
4. Rabbit IgG anti-Tau: Sigma-Aldrich, 1:100, cat. no. T6402. 
5. Rabbit polyclonal anti-Tbr1: Proteintech, 1:1000, cat. no. 20932-1-AP. 
6. Mouse monoclonal IgG βIII-tubulin (TuJ-1): Abcam, 1:2,000, cat. no. ab18207. 
2.3.6 Software 
1. ImageJ [155] 
2. ImageJ Plugin Straighten [95] 
3. MetaMorph (Molecular Devices) 
 
2.4 Methods 
2.4.1 Generating iPSCs 
The method for generating iPSC lines from human fibroblasts using episomal vectors is on the 
basis of the previous study from Dr. Yamanaka’s group [156].   
1. Combine 1 µg of each of the four plasmids (pCXLE-hOCT3/4-shp53, pCXLE-
hSK, pCXLE-hUL, pCXLE-EGFP) with 82 µL Human Dermal Fibroblast 
Nucleofector Solution, and 18µL supplement (from the Lonza NHDF Nucleofector 
Kit) for each line. 
2. When fibroblasts are roughly 90% confluent, trypsinize the cells, centrifuge 0.6 x 
106 cells and remove medium, and resuspend in the Nucleofector solution from 
step 1.  
3. Transfect the cells using a Nucleofector-2b with the program P-022. 
4. Allow cells to recover for 10 minutes, and then plate them onto a 6-well TC 
treated plate. 
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5. Replace MEF medium every 2 days  
6. On day 7, split cells onto a 10cm dish with a mouse embryonic fibroblast (MEFs) 
feeder layer. Change medium to hESC medium + 4 ng/mL bFGF. 
7. Around day 21, iPSC colonies should be large enough to be split. Carefully 
remove individual colonies using a sterile syringe and a P200 pipette tip, and 
plate each in its own well of a 12-well dish on MEF feeders. If possible, try to 
break up the colony a little bit before plating to increase the number of colonies. 
Try to collect at least 10 clones per line, most of which can be stored as backups. 
In general, 2-3 clones per line are enough to use for analysis, so the others can 
be stored in liquid nitrogen. 
8. Expand the separate clones and split to a 6-well dish when they colonies become 
large enough.  
 
2.4.2 Validating iPSC lines 
It is important to confirm that the generated iPSC lines are fully reprogrammed. A number of 
different methods can be employed to show this, however, we generally rely on staining for 
pluripotency markers such as Tra-1-60, SSEA4, and Nanog, and the teratoma assay [92].   
 
 
2.4.3 Differentiation to affected neuronal subtypes  
One of the main benefits of hPSCs is the ability to differentiate these cells to cell-types which 
are affected in disease of interest, in our case forebrain glutamatergic neurons. The steps below 
are summarized in Figure 2-1A.  
2.4.3.1 Days 0-4: Collecting hPSCs in suspension 
1. To generate telencephalic neurons from iPSCs, stem cells were cultured on a 
feeder layer of irradiated MEFs in 6-well tissue culture treated plates for around 6 
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days, with the hESC media (+10 ng/ml fibroblast growth factor [FGF]-2) changed 
daily.   
2. When nearly confluent, each well was washed once with 1 mL of PBS, then 1 mL 
of Dispase was added. Cells were incubated for around 3 minutes at 37°C, or 
until the edges of colonies begin to round up.  
3. The Dispase solution is removed and the wells are again washed with PBS, then 
hESC media is added.  
4. Next, scrape of the cells off of the well using a 10 mL glass pipette.  
5. Transfer the cells to a non-adherent T75 flask with roughly 50 mL of hESC 
medium (adjust depending on amount of cells).  Replace hESC medium every 
day.  
2.4.3.2 Days 5-8: Neural Specification 
1. Remove hESC medium and suspend cells in roughly 30 mL of NIM. Replace half 
of the media every other day.  
2.4.3.3 Days 9-16: Formation of neuroepithelial (NE) cells 
2. Next, the cells are plated onto 6-well dishes. Remove NIM and resuspend iPSC 
aggregates in enough NIM + 5% FBS so that 1.5 mL can be used for each well of 
a 6-well plate. Allow the aggregates to attach overnight, and in the next morning 
remove the media and replace with standard NIM. Replace media every other 
day until day 17. During this time, NE cells will develop, and form characteristic 
“rosette” structures, which resemble the neural tube. (Fig. 2-1B).  
3. It is also recommended to test the neural induction efficiency around day 10. To 
do this, staining for Pax6+ cells is recommended.  
2.4.3.4 Day 17-27: Specification of telencephalic (forebrain) neurons 
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4. On day 17, remove the NE cells by gently blowing media onto the colonies using 
a P1000 pipette. Collect the isolated NE cells and culture in suspension with NIM 
supplemented with 1:200 B27, 1:1,000 cAMP, and 1:10,000 IGF1.  
5. Replace half of the media every other day until day 27. Once a week, the 
neurospheres can be fragmented into smaller clusters by passing them through a 
P200 pipette several times.  
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Figure 2-1: Forebrain glutamatergic neuron differentiation. (A) Schematic of the neural 
differentiation protocol used in this study. Cell markers are shown above, and can be checked 
during the course of differentiation through immunocytochemistry. EBs = embryoid bodies, NE = 
neuroepithelium, NP = neuronal progenitors. (B) Representative images of cells at various 
stages of differentiation. Scale bar: 100 µm. (C) Efficient generation of Tbr1+ forebrain 
glutamatergic neurons, stained at 6 weeks. Images in B and C have been adapted from our 
previous publication [24]. Scale bar: 50 µm.  
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2.4.3.5  Day 28: Plating neurons 
6. Wash neurospheres with PBS one time, incubate in Accutase for 2 minutes at 
37°C.  
7. Add an equal volume of Trypsin Inhibitor solution, then centrifuge the cells for 2 
minutes at 400 x g.  
8. Remove the media and resuspend the neurospheres in 50 µL neural 
differentiation media (NDM). Pipette up and down several times with a P200 tip 
to dissociate the cells. Add additional NDM medium so there is a sufficient 
volume to reduce the density of cells.  
9. Add the cells to poly-ornithine/laminin coated coverslips and incubate cells for at 
least 2 hours at 37°C so that they have time to attach.  
10. Once attached, slowly add 500 µL of NDM to prevent cells from detaching. 
Replace 250 µL of NDM medium every other day until the cells are ready for 
analysis.  
 
2.4.4 Confirming the generation of forebrain glutamatergic neurons 
We perform immunostaining of the generated neurons around 6 weeks after differentiation 
began to determine the percentage of forebrain glutamatergic neurons that were generated 
using the markers that are listed in Fig. 1A. In Fig. 2-1C, Tbr1+ and βIII-tubulin+ cells are shown 
at 6 weeks. This step confirms that there is not a dramatic difference between control and 
mutant groups at generating these cells.  
 
2.4.5 Identifying disease-related phenotypes 
Once you are confident that the appropriate neuronal subtype has been generated, you can 
next begin to identify disease-related phenotypes in your mutant cells. We chose to look for 
axonal defects since HSP is associated with distal axonal degeneration [1]. The two methods 
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that we will discuss in detail are measuring neurite outgrowth and fast axonal transport of 
mitochondria.   
 
2.4.5.1 Measuring neurite outgrowth 
In order to look at initial neurite outgrowth, cells are analyzed just 48 hrs following plating 
onto coverslips, representative images are shown in Fig. 2-2A. This time point was also chosen 
because the coverslips will become too dense with neurites after longer periods to time, making 
it difficult to trace the morphology of individual cells.    
1. Plate dissociated neurons at a low density, and allow neurites to extend for 48 
hrs.  
2. Fix cells with 4% paraformaldehyde and stain cells for Tau and MAP2 to stain 
axons or dendrites respectively. 
3. Image the cells using a 20X objective and quantify neurite outgrowth using the 
NeuronJ plugin [96] for ImageJ.  
4. For each neuron, trace primary and secondary neurites. Axons can be identified 
as the longest neurite which also stains the strongest for Tau.  
 
2.4.5.2 Analyzing mitochondrial transport  
1. Plate dissociated neurons onto 35 cm glass-bottom dishes (Matek) following the 
steps as above.  
2. When the cells have matured sufficiently, stain the live cells with 50nM 
MitoTracker CMXRos for 3 minutes at 37°C. 
3. Wash the cells two times with NDM.  
4. Image cells using a 63X objected with a microscope that has a heated stage 
(37°C). 
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Figure 2-2: Neurons 48 hrs post plating stained for Tau. (A) These cells were plated at a 
good density, making it easy to trace neurites extending from each cell. Scale bar: 20 µm. (B) 
These cells were not adequately dissociated, and were cultured for 2 weeks after plating, 
causing the neurites to become too dense. Accurate tracing of neurites would be difficult with 
this image. Scale bar: 100 µm. 
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5. Visually identify axons based on morphological characteristics (constant thin 
diameter, long neurites, no branching and direct emergence from the cell body 
[157]). 
6. After identifying a suitable region, set up a time series by taking an image every 5 
sec for at least 5 min.  
7. Save the images as TIFs, and open all images within one series in ImageJ. 
Combine all images into a TIF stack (Image → Stacks → Images to Stack) 
8. Next, use the ImageJ plugin “Straighten” to straighten imaged axons (Fig. 2-3A) 
[95]. Be sure to start with the proximal portion of the axon, as this will appear on 
the left side of the generated image series, making it easier to calculate 
directional transport parameters. Adjust filament/wide line value so that the width 
of the neurite is completely covered. 
9. Open the straightened TIF series in MetaMorph and calibrate the scaling for the 
images.  
10. Open the Track Points app (Apps → Track Points) and first set the origin (Set 
Origin → Click on the far left side, towards the cell body → OK). Also set the 
interval to 5 sec (Set Interval → User defined → 5 seconds → OK) and configure 
set the program to record all parameters (Config Log → Enable All). 
11. Manually track the location of one mitochondrion within the axon for every frame 
in the series, then “Add Track” for the next mitochondrion. Repeat until the 
location of every mitochondrion within the axon has been tracked.  
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Figure 2-3: Analyzing mitochondrial transport. (A) Mitochondria within an axon imaged after 
staining with MitoTracker CMXRos. The cell soma was located to the left of the field. Bottom 
image shows results of the Straighten plugin in ImageJ. (B) Representative distance versus time 
kymograph generated in Metamorph. Scale bar: 10 µm.  
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12. Open Log 
13. Dynamic Data Exchange (opens Excel) → OK (keep default options) 
14. F9: Log Data 
15. Enters all of the Track Point data into Excel, grouped by each Track # 
(mitochondrion). 
16. Decide what parameters you are interested in: mean velocity, 
anterograde/retrograde velocity, motile events, anterograde/retrograde events, 
average run velocity, percentage motile mitochondria per cell, pause/run lengths. 
17. Manually calculate velocity with the equation below, since MetaMorph does not 
differentiate between anterograde and retrograde transport.  
=
(Distance from origin at current time + distance at previous time point) 
5 seconds
 
a. Positive values = anterograde transport 
b. Negative value = retrograde transport 
18. Determining motility events using a ≥±300 nm/sec threshold, which excludes 
events that may be mediated by actin based transport and should only include 
microtubule-based transport [157].  
19. If there are 3 consecutive motile events in one mitochondrion’s time series, than 
that mitochondrion is considered motile. 
20. Organize group data and compare control to mutant lines.  
21. A distance versus time kymograph can be generated in MetaMorph for graphical 
representation of mitochondrial transport (Fig. 2-3B).  
2.4.5.3 Measuring Mitochondrial Morphology 
 
1. The same straightened images generated for measuring mitochondrial transport 
can be used to analyze mitochondrial morphology. We generally only analyze the 
morphology of the mitochondria using the first image of each time series.  
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2. Within ImageJ, set the scaling of the image to match the objective used.  
3. Threshold the image so that all of the mitochondria are highlighted (Image → 
Adjust → Threshold) (Fig. 2-4) 
4. Remove mitochondria outside of cell of interest and delete any overlapping or 
aggregated mitochondria.  A protocol to segment mitochondria can be found in 
detail here [157].  
5. Next, use the Analyze Particles function using the following conditions.  
a. Size = 0.2-Infinity 
b. Circularity = 0-1 
c. Show = Ellipses 
6. Important results: area, major axis (length of mitochondrion), AR (aspect ratio) 
7. By measuring the length of each imaged axon, and dividing it by the number of 
mitochondria within that region, you can determine the mitochondrial density 
(mitochondria/µm axon).  
8. You can also calculate the distribution of mitochondria within axons. To do so, 
use the X,Y coordinates of the centroid of each mitochondrion and calculate the 
distance between adjacent mitochondria.  
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Figure 2-4: Analyzing mitochondrial morphology. Mitochondria within an axon before and 
after thresholding the image. Using the bottom image, the Analyze Particle function can 
calculate a number of useful mitochondrial morphology parameters. Scale bar: 10 µm.   
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2.5. Notes 
 
1. Depending on the type of mutation that is present in your iPSCs, it is often useful to 
generate hESC lines where a gene of interest is knocked down. These knockdown lines 
can be used to confirm that any phenotypes observed in mutant iPSC-derived cells are 
caused by haploinsufficiency and are not due to clonal variation. We design shRNAs 
using http://sirna.wi.mit.edu/ [91].  
2. To test the efficiency of neural induction, flow cytometry can be used to compare the 
percentages of Pax6+ cells between groups [158]. 
3. It is also recommended to stain and quantify the number of astrocytes (GFAP+) and 
oligodendrocytes (O4+) that are within neural cultures. This will ensure there are not 
dramatically different proportions of these cells between control and experimental 
groups.  
4. Depending on your disease of interest, a number of different neuronal subtypes can be 
generated besides forebrain glutamatergic neurons. These include spinal motor 
neurons [110] and dopaminergic neurons [159, 160]. It is often useful to compare 
affected neuronal subtypes to a subtype that is not affected in a particular disease, to 
show cell-type specific phenotypes in your system.  
5. Be sure to not plate neurons too densely for measuring neurite outgrowth, or it will be 
difficult to trace individual neurites (Fig. 2B). 
6. When imaging mitochondrial movement, take care to adjust the exposure time and light 
intensity to prevent photobleaching.  
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3.1 Abstract  
Human neuronal models of hereditary spastic paraplegias (HSP) that recapitulate disease-
specific axonal pathology hold the key to understanding why certain axons degenerate in 
patients and to developing therapies.  SPG4, the most common form of HSP, is caused by 
autosomal dominant mutations in the SPAST gene, which encodes the microtubule-severing 
ATPase spastin.  Here, we have generated a human neuronal model of SPG4 by establishing 
induced pluripotent stem cells (iPSCs) from an SPG4 patient and differentiating these cells into 
telencephalic glutamatergic neurons.  The SPG4 neurons displayed a significant increase in 
axonal swellings, which stained strongly for mitochondria and tau, indicating the accumulation of 
axonal transport cargoes.  In addition, mitochondrial transport was decreased in SPG4 neurons, 
revealing that these patient iPSC-derived neurons recapitulate disease-specific axonal 
phenotypes.  Interestingly, spastin protein levels were significantly decreased in SPG4 neurons, 
supporting a haploinsufficiency mechanism.  Furthermore, cortical neurons derived from 
spastin-knockdown human embryonic stem cells (hESCs) exhibited similar axonal swellings, 
confirming that the axonal defects can be caused by loss of spastin function.  These spastin-
knockdown hESCs serve as an additional model for studying HSP.  Finally, levels of stabilized 
acetylated-tubulin were significantly increased in SPG4 neurons.  Vinblastine, a microtubule-
destabilizing drug, rescued this axonal swelling phenotype in neurons derived from both SPG4 
iPSCs and spastin-knockdown hESCs. Thus, this study demonstrates the successful 
establishment of human pluripotent stem cell-based neuronal models of SPG4, which will be 
valuable for dissecting the pathogenic cellular mechanisms and screening compounds to rescue 
the axonal degeneration in HSP.  
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3.2 Introduction 
Hereditary spastic paraplegias (HSP) are a heterogeneous group of genetic disorders 
that result in progressive lower limb spasticity [161]. The symptoms are due to a length-
dependent axonopathy, most severely affecting corticospinal motor neurons (CSMN). These 
neurons display a “dying back” axonopathy, particularly in the spinal cord, resulting in impaired 
lower motor neuron function which produces prominent lower limb spasticity and typically more 
mild weakness.  Although there are 57 distinct genetic loci associated with HSP, SPG4 is the 
most common, accounting for nearly 40% of all cases of autosomal dominant HSP [55].  SPG4 
is caused by mutations in the SPAST gene, which encodes the microtubule-severing ATPase 
spastin [55, 162-164].  Spastin is a member of the ATPase associated with diverse cellular 
activities (AAA) family that also includes the microtubule-severing protein p60 katanin.  The 
large variety of mutation types present in the SPAST gene of SPG4 patients has led to different 
hypotheses for the pathogenic mechanism of these mutations. The majority are nonsense 
mutations, deletions, or splice-site mutations.  These are believed to reduce the amount of 
spastin present in a cell, causing disease through a haploinsufficiency mechanism [63]. This 
seems to be true for the majority of cases; however, there are certain missense mutations  in 
the AAA ATPase domain that appear to act in a dominant-negative, loss-of-function fashion 
[165], which is possible because spastin functions as a hexamer [67]. Spastin is involved in a 
variety of functions, including microtubule dynamics [66], membrane remodeling [65], 
cytokinesis [64, 65], neurite outgrowth [166], and axonal transport [29, 61, 68, 167]. 
A common observation researchers have made while studying SPG4 is that spastin 
affects microtubule-based transport. This fits with the role spastin plays in microtubule severing, 
as microtubule arrays are present through the entire length of axons and both provide structural 
support and serve as the railways for organelle transport.  Axonal transport deficits also neatly 
match the observation that only the longest projection neurons are affected, since they would 
put the largest strain on transport systems to deliver cellular contents to the most distal portions 
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of the cell.  If materials are not properly delivered to the distal regions, it could cause a dying-
back degeneration of the axon, as seen in HSP.  Some of the best lines of evidence linking 
spastin and transport come from two different HSP mouse models that possess different spastin 
mutations [29, 68].  These studies showed that cortical neurons cultured in vitro could be used 
to model axonal defects, although the mechanisms underlying the axonal defects in SPG4 
remain largely unknown. 
 To date, the role of spastin has not been investigated in human cortical neurons, but the 
advent of induced pluripotent stem cell technology [106, 107]  now provides researchers with a 
system for studying the specific cell types that are affected by various diseases in vitro. This 
method has been employed for several neurodegenerative disorders including spinal muscular 
atrophy [119], amyotrophic lateral sclerosis [168], Parkinson disease [169], and Huntington 
disease [120].  Here, we for the first time generated human iPSCs from an SPG4 patient as well 
as spastin knockdown hESCs to model HSP.  The generated human pluripotent stem cell 
(hPSC) lines serve as a renewable source of cells that can be differentiated into forebrain 
projection neurons, which include the most severely affected corticospinal motor neurons in 
HSP.  In neurons generated from SPG4 iPSC lines, we observed an increase in the number of 
axonal swellings and accumulation of mitochondria within these regions, leading us to quantify 
fast axonal transport.  This revealed a significant decrease in the number of motile mitochondria 
in the SPG4-derived neurons, and decreased motile events in the retrograde direction.  It 
appears as if these defects were due to spastin haploinsufficiency, as the level of spastin 
protein was significantly decreased in the SPG4-derived neurons.  To confirm that loss of 
spastin function is implicated in the pathogenesis of SPG4, we examined spastin knockdown 
neurons, and found a similar increase in axonal swellings.  Lastly, to show that these cells will 
be useful as a drug screening platform, we treated iPSC-derived and spastin knockdown 
neurons with the microtubule-destabilizing drug vinblastine.  This treatment led to a significant 
reduction in axonal swellings as compared to vehicle-treated cells.  These findings suggest that 
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these hPSC-based models of SPG4 will serve as a useful model for HSP, since no therapies 
exist that can prevent, slow the progression, or cure HSP. 
 
3.3 Materials and Methods 
3.3.1 Reprogramming human fibroblasts into iPSC lines. Human iPSC lines were 
established from human fibroblasts by transfecting them with excisable lentiviruses (kindly 
provided by Dr. Gustavo Mostoslavsky) [170, 171] or episomal plasmids (Addgene), as reported 
previously [156]. Briefly, human fibroblasts collected under an IRB-approved clinical protocol 
(NINDS protocol 00-N-0043) at the NIH Clinical Center were seeded at ~105 cells/ 35-mm dish 
in DMEM supplemented with 10% fetal bovine serum (FBS) and 0.1 mM non-essential amino 
acids.  For lentiviral infection, cells were infected with EF1α-hSTEMCCA-loxP lentiviruses 
containing pluripotency genes (Oct4, Sox2, c-Myc, Klf4).  For episomal transduction, human 
fibroblasts (~200,000) were dissociated and then infected with episomal plasmids containing 
pluripotency factors (Oct3/4, Sox2, L-Myc, Klf4, and Lin 28). At around 1 week after lentiviral 
infection or electroporation transduction, cells were plated onto a 35-mm dish in DMEM 
supplemented with 10% FBS. After culturing for 7 days, cells were dissociated and seeded onto 
mouse embryonic fibroblast (MEF) feeder at ~105 cells/100-mm dish. Two weeks later, colonies 
with morphologies similar to hESCs were observed.  These colonies were split onto MEF feeder 
cells to derive iPSC lines.  After several passages, homogenous colonies with ESC-like 
morphology were generated. The lentiviral iPSC lines used in this study were iWT-l1, iSPG4-l4, 
and iSPG4-l7.  The episomal iPSC lines used in this study were iWT-e1, iWT-e3, iSPG4-e6, and 
iSPG4-e8. 
 
3.3.2 Lentivirus production and transduction of hESCs. To produce high-titer lentivirus, 10 
µg of lentiviral transfer vector (pLVTHM), 7.5 µg of lentiviral vector psPAX2, and 5 µg of 
pMD2.G (VSV-G envelope protein) were cotransfected into HEK293FT cells (Invitrogen) using 
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the calcium phosphate method.  Sixty hours after transfection, cell culture medium containing 
viral particles was collected and filtered through a 0.45-µm filter (Millipore).  Viral particles were 
further concentrated by ultracentrifugation (SW 28 rotor, Beckman) at 50,000 g for 2 h, and the 
pellet was resuspended in hESC medium.  For transduction of ESCs, hESCs were passaged 
normally and pelleted by brief centrifugation.  Cell pellets were then incubated with 100 µl of 
concentrated virus (106 transducing units/ml) at 37°C for 30 min. To knock down spastin, 
pLVTHM lentiviruses contain shRNA targeting spastin or luciferase (as control) were used to 
infect hESCs, a strategy similar to that we have used for knocking down other genes [158]. 
RNAi hESCs were expanded and then differentiated as described below. 
 
3.3.3 hPSC Neural Differentiation. To generate telencephalic projection neurons from hPSCs, 
stem cells were cultured on a feeder layer of irradiated MEFs in 6-well tissue culture treated 
plates for around 6 days, with the hESC media (+10µg/ml FGF-2) changed daily.  When almost 
confluent, cells were detached from the feeder layer to initiate the neural differentiation, as we 
previously described [128, 172, 173]. The cells were cultured in suspension for 4 days in hESC 
media, changing the media every day.  On day 5, neural induction was started by transferring 
the generated PSC aggregates to neural induction media (NIM).  After 3 additional days in 
suspension, PSC aggregates were plated onto 6-well tissue culture treated plates in NIM with 
10% FBS.  After 12 hours, the media was changed with fresh NIM. The media was then 
changed every other day until day 17, when the generated neuroepithelial (NE) cells were 
isolated.  Mechanically-isolated NE cells were cultured in suspension with NIM (+B27, +cyclic 
AMP, +insulin-like growth factor 1 [IGF1]) to generate neurospheres for at least an additional 10 
days.  On about day 28, the neurospheres were dissociated and plated onto polyornithine- and 
laminin-coated coverslips in neural differentiation media (NDM) containing N2, B27, ascorbic 
acid, cyclic AMP, laminin, IGF1, brain-derived neurotrophic factor, and glial-derived neurotrophic 
factor.  Half of the media was changed every other day for a total of 6 to 12 weeks, depending 
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on the analysis to be performed. To treat cells with vinblastine, the media was replaced with 
standard NDM with 10 nM vinblastine (Sigma-Aldrich) dissolved in water. 
 
3.3.4 Immunocytochemistry. Cells on glass coverslips are fixed with 4% paraformaldehyde for 
20 minutes.  A 0.2% Triton-X solution was used to permeabilize the cells for 10 minutes 
followed by several PBS washes.  The samples are incubated in a primary antibody solution 
overnight.  On the following day, samples are incubated with the appropriate secondary 
antibody for 30 minutes [128].  To quantify axonal swellings, at least three blindly-selected fields 
were imaged for at least three coverslips per group. The number of axonal swellings were 
counted and divided by the total length of Tau+ axons in each field, which were measured using 
MetaMorph software. 
 
3.3.5 Antibodies. Mouse IgM anti-Tra-1-60 (Santa Cruz, 1:50), goat IgG anti-Nanog (R&D, 
1:500), mouse IgG3 anti-SSEA-4 (DSHB, 1:100), mouse IgG anti-acetylated tubulin (Sigma-
Aldrich, 1:10,000), rabbit IgG anti-Tau (Sigma-Aldrich, 1:100), rat IgG2a anti-GFP (Nacalai 
Tesque, 1:1000), rabbit IgG anti-Tbr1 (Proteintech, 1:1,000), βIII-tubulin, mouse IgG (DSHB, 
1:100). 
 
3.3.6 Reverse transcriptase Polymerase Chain Reaction (RT-PCR). RNA was isolated from 
cells using TRIzol reagent (Invitrogen) following manufacturer’s instructions. A total of 2µg of 
RNA was used to synthesize cDNA using iScriptcDNA Synthesis Kit (Bio-Rad) following 
manufacturer’s parameters: 5 min @ 25°C, 30 min @ 42°C, and 5 min @ 85°C. Semi-
quantitative analysis was performed using RT-PCR with GoTaq Green Master Mix (Promega). 
 
3.3.7 Western Blotting.  We used a general protocol that was described previously [174].  A 
mouse monoclonal anti-spastin antibody (Sigma-Aldrich, 1:1000) was used to detect expression 
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of spastin isoforms, and a mouse monoclonal anti-actin antibody (Sigma-Aldrich, 1:1000) was 
used as a loading control. The quantification of Western blotting was quantified using ImageJ 
[155] normalized against actin as a loading control. 
 
3.3.8 Live Cell Imaging with MitoTracker. Neurospheres are plated onto polyornithine and 
laminin coated 35mm dishes (MatTek). At 8 weeks of total differentiation, the cells are stained 
with 50 nM MitoTracker Red CMXRos (Invitrogen) for 3 minutes to allow visualization of 
mitochondria and then the media is replaced with fresh NDM.  Live-cell imaging was performed 
using a Carl Zeiss Axiovert 200M microscope equipped with an incubation chamber.  The cells 
are kept at 37°C with 5% CO2 while imaging.  Axons identified according to morphological 
criteria (constant thin diameter, long neurites, no branching and direct emergence from the cell 
body) were imaged every 5 seconds for 5 minutes, yielding 60 frames.  Quantifications were 
performed using the same protocol as described previously [133].  In short, the location of each 
mitochondrion was manually selected using the Track Points function in MetaMorph, and 
parameters such as distance from cell body and velocity were recorded. A velocity threshold of 
300 nm/s was used to select microtubule based transport events [157]. To determine the 
percentage of motile mitochondria, the total number of mitochondria that were present along the 
imaged neurite was counted, and those that changed position (velocity >300 nm/s) in at least 3 
consecutive frames were considered motile. 
 
3.3.9 Statistical analysis. The statistical significance in mean values among multiple sample 
groups was analyzed with Turkey’s studentized range test after ANOVA. Two-sided t-test was 
used to examine the statistical significance between two sample groups. The trend between 
knockdown efficiency and increased swellings was tested using linear regression analysis. The 
significance level was defined as p < 0.05, and all significance tests were conducted using SAS 
9.1 (SAS Institute).
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3.4 Results 
3.4.1 Characterization and differentiation of control and SPG4 iPSC lines 
SPG4 iPSCs were generated from dermal fibroblasts of an SPG4 patient with a 
heterozygous G>T substitution located in intron 4 of the SPAST gene that alters the splice 
acceptor site (c.683-1G>T).  The fibroblasts were reprogrammed to iPSCs using both a lentiviral 
[170, 175] and an episomal method [156], which permitted us to determine if the reprogramming 
method has any effect on the mutant phenotypes that we observe in the SPG4 neurons.  
Human iPSC lines derived from normal individuals were also generated and utilized as controls.  
All of the clones that we analyzed, from SPG4 and controls (wild-type [WT]), displayed 
characteristic colony morphology and stained positive for the pluripotency markers Nanog, Tra-
1-60, and SSEA4 (Fig. 3-1A). The expression of pluripotency genes was analyzed by RT-PCR 
(Fig. 3-1B); only in the iPSCs was expression of Sox2, Nanog, or Oct4 detected.  Teratomas 
were generated in mice using the iPSC lines to confirm that they were pluripotent.  Both the 
lentiviral and episomal iPSC lines were able to spontaneously differentiate into tissues of each 
of the three germ layers, confirming pluripotency (Fig. 3-1C).  The region surrounding the splice 
acceptor site of intron 4 was sequenced to confirm that the SPG4-derived iPSC lines maintained 
the mutation in the SPAST gene after reprogramming (Fig. 3-1D).  Because it is known that 
iPSCs are susceptible to chromosomal abnormalities after passaging, karyotype analysis was 
performed, which did not reveal any defects (Fig. 3-1E). 
Next, the iPSC lines were differentiated to the neural lineage to generate forebrain 
glutamatergic neurons using a protocol we established previously, which leads to the efficient 
generation of telencephalic neurons [128, 172, 173].  Both control and SPG4 iPSCs efficiently 
differentiated into neurons with long processes, regardless of the reprogramming method (Fig. 
3-1F).  These neurons were Tbr1+, confirming that they are glutamatergic (Fig. 3-1F).  There 
were no significant differences in the percentages of Tbr1+ cells between control and SPG4 cells 
(Fig. 3-1G).  Since the spastin mutation in this SPG4 patient would affect RNA splicing, we 
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performed western blot analysis to examine the levels of spastin present in neurons generated 
from the iPSCs.  Our data showed a reduction in spastin protein levels in the neurons derived 
from the SPG4 patient lines as compared to controls (~47% of control; Fig. 3-1H).  Since SPG4 
is caused by autosomal dominant mutations, SPG4 patients likely have ~50% of spastin activity 
if one allele is non-functional.  Thus, the SPG4 iPSC-derived neurons track level of spastin 
expected in patients, providing a unique model to study the pathological changes caused by 
reduced spastin levels.  
 
3.4.2 Neurons derived from SPG4 iPSCs exhibit increased axonal swellings 
A common pathologic hallmark of SPG4 is the enlargement of axons that accumulate 
organelles, termed axonal swellings [68].  To determine if the iPSC-derived neurons displayed 
axonal phenotypes similar to that observed in post mortem spinal cord sections, we performed 
acetylated tubulin staining to examine the formation of axonal swellings (Fig. 3-2A).  Our 
analysis showed that there was a substantial increase in the number of axonal swellings in the 
SPG4-derived neurons as compared to controls (Fig. 3-2B).  Furthermore, the axons with 
swellings in SPG4 neurons were significantly longer than those without (SPG4 axons without 
swellings = 53.16±2.88 µm vs. those with swellings = 93.04±5.87 µm; p<0.01), suggesting that 
longer axons were more susceptible to these changes.  Similar swellings were present in the 
neurons derived from the episomal SPG4 iPSC lines, indicating that the reprogramming method 
did not affect this phenotype (Fig. 3-2C).  It is plausible that reduced levels of a microtubule-
severing enzyme, like spastin, would lead to increased microtubule stability.  To test this, we 
performed Western analysis for stabilized microtubules in extracts from week 6 iPSC-derived 
neurons, using an acetylated tubulin antibody.  This revealed a dramatic increase in acetylated 
tubulin levels in the SPG4 patient-derived neurons as compared to controls (Fig. 3-2D).  
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Figure 3-1 
Characterization and differentiation of SPG4 iPSCs.  (A) Control (iWT-l1, lentiviral) and SPG4 
iPSC lines expressed the hESC markers Tra-1-60, Nanog and SSEA-4. Scale bars: 100 µm.  
(B) Analysis of pluripotency genes in generated iPSC lines (iWT-e3, iWT-e6, iSPG4-e3, iSPG4-
e6, episomal) by RT-PCR. (C) Hematoxylin and eosin staining of teratoma sections that were 
derived from iPSCs. Tissues from each germ layer were formed. Scale bars: 200µm.  (D) 
Sequencing results confirmed the presence of the intron 4 splice acceptor mutation (c.683-
1G>T), which was not found in control cells.  (E) The lentiviral SPG4 lines maintained a normal 
46,XX female karyotype after 10 passages as shown by G-banded analysis.  (F) The iPSCs 
were able to efficiently generate telencephalic glutamatergic neurons, as shown by staining for 
Tbr1. Scale bars: 50µm.  (G) Percentages of cells immunostained positive for Tbr1 in control 
(iWT-l1) and SPG4 lines (iSPG4-l4 and iSPG4-l7). Data presented as mean ±SD.  (H) Western 
blot analysis revealed a significant decrease in spastin protein in post-mitotic neurons derived 
from SPG4 iPSCs compared to control neurons. Nuclei are labeled with Hoechst (blue) in A and 
F. 
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3.4.3 Fast axonal transport of mitochondria is disrupted in SPG4 neurons  
Axonal swellings have been associated with the accumulation of transported cargos [29, 
68], indicating that axonal transport may be impaired. To assess axonal transport in SPG4 
iPSC-derived cortical neurons, we firstly performed immunostaining for mitochondria and 
acetylated tubulin.  This revealed the accumulation of mitochondrial staining within axonal 
swellings (Fig. 3-3A), suggesting impaired transport of these organelles.  To further analyze 
mitochondrial fast axonal transport, live cell imaging was performed on week 8 control and 
SPG4-derived neurons. Images of axons were taken every 5 seconds for 5 minutes.  As shown 
in representative kymographs of mitochondria within proximal axons (Fig. 3-3B), a significant 
decrease in the mitochondrial movement (indicated along the X-axis) was observed in neurons 
derived from SPG4 iPSCs.  Further analysis of individual trajectories of each mitochondria 
revealed a significant reduction in the percentage of motile mitochondria; in control iPSC-
derived neurons, 10.5% of the mitochondria were motile, compared to just 3.4% in the SPG4-
derived neurons (Fig. 3-3C). 
 
Transport vesicles and membranous organelles move along a polarized array of 
cytoplasmic microtubules down the axon (anterograde transport) and back to the cell body 
(retrograde transport).  It remains unclear whether anterograde or retrograde transport is 
affected in SPG4. Therefore, using these patient iPSC-derived neurons, we further analyzed the 
velocity of motile mitochondria and frequency of motile movements in both the anterograde and 
retrograde directions (Table 3-1).  The mitochondrial transport velocity in both anterograde and 
retrograde direction did not differ between control and SPG4 neurons, suggesting that the 
ATPase activity of the molecular motors was unaffected. Next, the frequency of fast axonal 
transport events was calculated; there was a 68% reduction in the frequency of motile events in 
the SPG4-derived neurons as compared to controls. Subdivision into anterograde and
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Figure 3-2 
SPG4 patient-derived neurons display axonal defects. (A) Acetylated tubulin staining revealed 
the presence of swellings along Tau+ axons of 6 week-old neurons. Boxed areas are enlarged in 
insets. (B) Quantification revealed a significant increase in axonal swellings in patient-derived 
neurons compared to control neurons. Data presented as mean ±SD. **P < 0.01. (C) Episomal 
SPG4 neurons also possessed axonal swellings.  (D) Western blots show that acetylated tubulin 
levels were dramatically increased in the week 6 SPG4-derived neurons compared to controls. 
Scale bars: 20 µm. 
 56  
 
 
Figure 3-3 
Disrupted fast axonal transport in SPG4-derived neurons.  (A) Staining for mitochondria, using 
MitoTracker Red CMXRos, was enriched within axonal swellings (arrowheads). Scale bars: 20 
µm.  (B) Representative distance versus time kymographs over a 5 minute recording. Scale bar: 
10 µm.  (C) Quantification of motile mitochondria in week 8 forebrain neurons. Data presented 
as mean ±SD. **P < 0.01.  
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retrograde events revealed a directional selectivity in the effect of reduced spastin activity on 
fast axonal transport.  While the number of anterograde events above the velocity threshold was 
not significantly different between control and SPG4 cells (though there was a trend toward 
reduction), there was a prominent 80% reduction in the number of retrograde events in the 
SPG4 cells, implicating retrograde axonal transport in SPG4 pathogenesis. 
 
3.4.4 Knocking down spastin leads to axonal defects similar to those in SPG4-derived 
neurons 
Considering that SPG4 iPSC-derived neurons recapitulate the disease-specific 
phenotypes and that the spastin protein is significantly reduced in these neurons, the axonal 
defects in SPG4 may result from loss of spastin function.  To test this, we established spastin-
knockdown hESC lines using lentiviral infection of shRNA constructs (Fig. 3-4A).  To minimize 
off-target effects, two shRNAs targeted against different regions of spastin were cloned into the 
pLVTHM lentiviral vector that allows for the simultaneous expression of GFP and shRNA. After 
infecting H9 hESCs with the corresponding lentivirus, GFP+ cells were selected to obtain a pure 
population of knockdown cells (Fig. 3-4B).  The spastin knockdown hESCs, as well as the 
control luciferase RNAi hESCs, were differentiated to the neural lineage and glutamatergic 
neurons as we described for SPG4 iPSCs.  Expression of the shRNA was maintained during 
neural differentiation, as GFP was robustly expressed (Fig. 3-4B).  To confirm the knockdown 
efficiency of the shRNA constructs, Western analysis was performed on cells at the hESC stage 
and in differentiated neurons (Fig. 3-4C). In day 40 neurons, there was around 40% and 77% 
knockdown of spastin protein level in the spastin RNAi lines 1 and 2, respectively.  Notably, 
when the morphology of the neurons was examined, axonal swellings were prominent in 
neurons from the two spastin knockdown lines (Fig. 3-4D). Quantification revealed a significant 
increase in the number of swellings in the cells with reduced spastin as compared to controls 
(Fig. 3-4E). Interestingly, there was a trend toward increased swellings, with the knockdown
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Table 3-1: SPG4-derived neurons have decreased frequency of retrograde fast axonal transport 
motile events. 
 
 
 
 
 
 
 
 
 
 
The velocity and frequency of mitochondrial motility were quantified in week 8 control and 
SPG4-derived neurons. No velocity differences were found in either the anterograde or 
retrograde direction. The frequency of total motile events was significantly decreased in SPG4 
neurons. Though there was a non-significant trend toward reduction of anterograde motile 
events in SPG4 neurons, retrograde events were significantly reduced. Data are presented as 
means ±SEM. Statistical significance was determined using a two-sided t-test. 
 
 
Anterograde 
Motile Velocity 
(µm/s) 
Retrograde 
Motile 
Velocity 
(µm/s) 
Events 
(>300 
nm/s) 
Anterograde 
Events (>300 
nm/s) 
Retrograde 
Events 
(>300 nm/s) 
iGM-e3 0.48±0.21 0.50±0.19 0.43±0.09 0.15±0.04 0.29±0.07 
iSPG4-
e6 
0.45±0.12 0.54±0.17 0.14±0.04 0.08±0.02 0.06±0.02 
P-value ns ns <0.01 ns <0.01 
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efficiency (p<0.01 by linear regression analysis).  These data confirm that loss of spastin 
function results in the disease-specific axonal pathological changes in hPSC-derived neurons.    
 
3.4.5 Microtubule-destabilizing drug rescues the axonal swelling phenotype 
In order to show that the cells generated in this study have utility in screening for potential 
therapeutic compounds, we treated SPG4 iPSC-derived neurons and spastin knockdown hESC-
derived neurons with the microtubule-destabilizing drug vinblastine.  Vinblastine has been 
shown to be efficacious at reducing axonal swellings in SPG4Δ/Δ primary mouse neurons [167], 
increasing the cell body size of olfactory neural progenitors from SPG4 patients [176], and 
ameliorating the neurodegenerative phenotypes in Drosophila [177].  When week 8 iSPG4-l7 
neurons were treated with 10 nM vinblastine for just 24 hours, there appeared to be a reduction 
in the number of axonal swellings (Fig. 3-5A), and quantification confirmed that vinblastine 
significantly reduced the number of axonal swellings in these cells (Fig. 3-5B). To confirm the 
protective effect of vinblastine against axonal defects in human neurons, we treated week 10 
spastin knockdown neurons with vinblastine (Fig. 3-5C).  Similar to the iPSC-derived neurons, 
vinblastine treatment significantly reduced the number of axonal swellings (Fig. 3-5D). Taken 
together, our data revealed that a nanomolar concentration of the microtubule-destabilizing drug 
vinblastine can ameliorate the axonal defects observed in this human neuronal model of SPG4. 
This implicates disorganization of microtubules in the axonal phenotypes of SPG4.  
 
3.5 Discussion 
 Human pluripotent stem cells, including hESCs and iPSCs, can differentiate into any cell 
type in the body, including neurons.  Based on developmental principles, different neuronal 
subtypes have been generated using in vitro differentiation protocols.  Using these systems, 
PSCs have been used to model several neurogenetic disorders [119, 120, 178-186], via   
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Figure 3-4 
Spastin knockdown in hESC-derived neurons recapitulates SPG4 patient phenotype.  (A) 
Schematic map showing the pLVTHM vector with the shRNA sequence. H9 hESCs were 
transfected with the indicated lentivirus, and GFP+ cells were selected.  (B) hESC colony after 
lentiviral transfection shows efficient generation of knockdown lines. Expression of shRNA 
continued during differentiation. Scale bars: 100 µm.  (C) Western blot analysis confirming 
knockdown of spastin in both hESCs and neurons after 40 days of differentiation.  (D) 
Immunostaining for acetylated tubulin revealed the development of axonal swellings in two 
spastin RNAi hESC-derived neurons. Hoechst stains the nuclei. Scale bars: 20µm.  (E) 
Quantification of axonal swellings shows a significant increase in spastin RNAi-derived neurons 
compared to control cells. Data presented as mean ±SD. *P < 0.05, **P < 0.01. Luc, luciferase. 
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genetically modifying hESCs or using patient-specific iPSCs and then differentiating these stem 
cells into the neurons affected by a particular disease.  Here, we have differentiated SPG4 
iPSCs and spastin-knockdown hESCs to forebrain projection neurons in order to model HSP.  
We generated iPSCs from an SPG4 patient who possesses a heterozygous mutation (c.683-
1G>T) that affects mRNA splicing, resulting in a reduction in spastin levels.  Neurons from these 
lines had a significant increase in axonal swellings which appeared to accumulate mitochondria, 
suggesting altered axonal transport in these regions.  Analysis of fast axonal transport of 
mitochondria revealed a significant decrease in the percentage of motile mitochondria and a 
decrease in the frequency of motile events, particularly in the retrograde direction.   
 
To confirm that spastin loss-of-function is responsible for these findings, we generated 
spastin knockdown lines.  Similarly, a significant increase in axonal swellings was found in the 
knockdown cells compared to a control knockdown line.  Moreover, it appeared that cells with 
the greater reduction in spastin levels exhibited that largest increase in swellings.  In addition, 
the protein expression of stable acetylated tubulin was increased in SPG4 neurons.  Treatment 
with the microtubule-destabilizing drug vinblastine was able to rescue the axonal swelling 
phenotype in SPG4 and spastin-knockdown neurons.  To our knowledge, this is the first study to 
recapitulate the axonal defects of HSP in human neurons.  Our study also implicates the loss of 
spastin function and subsequent disruption in microtubule organization in the axonal defects in 
SPG4 neurons.  
Our results support the hypothesis that spastin loss-of-function is responsible for 
mediating disease in SPG4 patients. There was a dramatic decrease in spastin levels in the 
neurons generated from the SPG4 iPSC lines as compared to lines from control individuals.  In 
addition, SPG4-derived neurons with reduced spastin displayed a significant increase in axonal 
swellings. Interestingly, the axons that possessed swellings were significantly longer than those
 62  
 
 
Figure 3-5 
Vinblastine treatment ameliorates the SPG4 axonal swelling phenotype.  (A) Week 8 iSPG4-l7 
neurons treated with 10 nM vinblastine for 24 hours appeared to have a reduction in axonal 
swellings compared to control cells, while no deleterious effects were observed. Scale bars: 
20µm.  (B) Quantification revealed that 10 nM vinblastine significantly reduced the number of 
axonal swellings.  (C) Treatment with 10 nM vinblastine for 24 hours also reduced axonal 
swellings in spastin RNAi-1 neurons. Scale bars: 20µm.  (D) Quantification of axonal swellings 
in cells treated with vehicle or 10 nM vinblastine. Data presented as mean ±SD. **P < 0.01.  
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without, suggesting that the longer axons may be more susceptible to defects caused by 
reduced spastin levels.  This is concordant with the length-dependent degeneration of the 
longest CSMN axons in SPG4.  Notably, we were able to observe a similar increase in swellings 
in neurons from spastin knockdown lines, suggesting that this phenotype was dependent on 
spastin dosage.  The presence of axonal swellings in our system, at as early as 6 weeks of 
differentiation, is very interesting.  Neurons at this stage are comparable to immature fetal cells 
[187], suggesting that defects in patient cells may be present prior to the onset of symptoms.  
An alternative explanation for this may be the inherent differences in the in vitro environment 
compared to in vivo environment, which may affect the onset and severity of the phenotype.  
Our findings are in agreement with the published studies of two SPG4 mouse models, where a 
reduction in spastin also led to phenotypes similar to HSP patients and axonal swellings in 
cortical neurons [29, 68].  Although the knockout mice only had minor motor deficits compared 
to those of HSP patients, perhaps the prominent differences in absolute size of CSMNs in mice 
and humans can account for this.  One of the difficulties in examining CSMNs using in vitro 
cultures is the lack of a specific marker, and a directed differentiation method that specifically 
generates CSMNs is currently unavailable.  However, the differentiation method used in this 
study can produce neurons that express factors enriched in these cells [128], such as FezF2 
and Ctip2 [188].   In the future, if conditions for specifying CSMNs are established, it would be 
interesting to determine whether these neurons are more susceptible to axonal swellings than 
other neuronal subtypes.  
Microtubules are a major component of the neuronal cytoskeleton, and they are needed 
for the extension of neurites in developing neurons and to serve as railways for cargo transport 
in mature neurons [189, 190].  They are composed of α- and β-tubulin heterodimers that are 
selectively arranged in axons so that the plus-end is oriented distal to the soma.  All forms of α-
tubulin can be acetylated at Lys40, while β-tubulin is not.  Long-lived, stable microtubules are 
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enriched in acetylated tubulin [191], particularly in the proximal portion of axons [192].  Although 
the exact role of tubulin acetylation has not been fully resolved, studies on Huntington and 
Parkinson disease models have reported that altered levels of acetylated tubulin result in axonal 
transport deficits [193, 194].  We found that levels of acetylated tubulin were dramatically 
increased in SPG4-derived week 6 neurons compared to control neurons.  Reduction in the 
microtubule-severing activity of spastin in the SPG4-derived neurons would be expected to 
cause such an increase in stabilized microtubules.  This result is contrary to what was observed 
in olfactory neurosphere-derived cells isolated from SPG4 patients [176], where a decrease in 
acetylated tubulin in SPG4 cells was reported to reflect an increased expression of the 
microtubule-destabilizing protein stathmin.  Differences in the cell types that were analyzed 
between these two studies may account for the opposing changes in acetylated tubulin levels.  
This further suggests that differentiating cells to mature neurons that possess axons may be 
important for recapitulating disease-specific abnormalities.  
Deficits in axonal transport are a common observation among different forms of 
neurodegenerative disorders. This is not surprising, since the axoplasm accounts for >99% of  
total cellular volume in the longest neurons, which puts enormous strain on the intracellular 
transport mechanisms needed to traffic proteins, lipids, and other molecules to and from the 
most distal parts of the cell [132].  Microtubule-severing enzymes are involved in generating the 
diverse array of microtubules present in axons [195].  As revealed in our study, levels of 
acetylated tubulin were significantly increased in SPG4 neural cultures.  In SpΔ/Δ mice, loss of 
spastin leads to a decrease in dynamic microtubule ends, and an increase in detyrosinated, 
stable microtubules along axonal swellings [29].  These changes can lead to alterations in 
microtubule-associated protein (MAP), kinesin, and dynein binding [189]. The decrease in motile 
mitochondria we observed in SPG4-derived neurons supports a pathogenic role for disrupted 
microtubule-based transport in SPG4.  Moreover, although the velocity of fast axonal transport 
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was not altered, the frequency of motile events in the retrograde direction in particular was 
significantly decreased.  Importantly, longer-lived, stable microtubules that are subjected to 
post-translational modifications and MAP binding may interfere with the binding of molecular 
motors, altering the frequency of motility events [196]. Retrograde axonal transport is important 
for bringing distal trophic factors or stress stimuli to the soma so that the neuron can respond 
properly [197]. Our finding agrees with a recent report on an SPG4 mouse model, SpΔ/Δ, where 
retrograde transport was also specifically affected in neurons that lack spastin [13].  Moreover, 
fast axonal transport deficits are implicated in other related neurodegenerative diseases.  For 
example, mutations in subunits of cytoplasmic dynein, a motor protein involved in retrograde 
transport, can result in motor neuron degeneration, suggesting that retrograde fast axonal 
deficits are sufficient to cause neurodegeneration [198, 199]. 
In the future, these SPG4 iPSCs should prove valuable in further unraveling the 
mechanisms of axonal degeneration in HSP. Understanding the link between microtubule 
defects found in SPG4 and other forms of HSP will be valuable in understanding the pathways 
required for axonal maintenance. A better notion of the pathways that spastin regulates will be 
useful in the development of therapies that may be applicable to multiple forms of HSP. This 
includes the other forms that are involved in ER morphogenesis: SPG3A, SPG12, and SPG31 
[69, 70, 78]. In addition, this hPSC model of HSP will also be a valuable tool in testing future 
therapeutic strategies. The ability to examine the effects of drugs on the human cell types that 
are affected by disease is one of the main benefits of using hPSCs. This is particularly important 
since over 90% of CNS therapies fail during clinical trials, in part because of the lack of accurate 
models during preclinical stages [187, 200].  The evidence that vinblastine is capable of 
reducing axonal swellings in human cortical neurons shows that this system will be useful in the 
future for screening therapeutic agents to rescue axonal degeneration in HSP. 
 
 66  
3.6 Conclusion 
In this study, we have demonstrated the successful establishment of human neuronal models of 
SPG4 by generating both SPG4 patient-iPSCs and spastin-knockdown hESCs, and then 
differentiating these stem cells into telencephalic glutamatergic neurons. These hPSC-derived 
neurons displayed increased axonal swellings, accumulation of transported cargoes, and 
impaired mitochondrial transport, recapitulating disease-specific axonal phenotypes. To our 
knowledge, this is the first evidence of axonal transport deficits in human SPG4 neurons. 
Moreover, our data support the hypothesis that axonal phenotypes in SPG4 are caused by loss 
of spastin function, which is buttressed by both the decreased expression level of spastin in 
SPG4 iPSC-derived neurons and the observation of similar axonal phenotypes in spastin-
knockdown neurons. Finally, the expression of stable acetylated-tubulin was increased in SPG4 
neurons, and vinblastine, a microtubule-destabilizing drug, rescued the axonal swelling 
phenotype. These findings suggest that microtubules can be a potential therapeutic target for 
HSP in human neurons and our hPSC-based models of HSP serve as a unique paradigm to 
study the pathogenic mechanisms and to screen for therapeutic drugs. 
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4.1 Abstract 
Hereditary spastic paraplegias (HSPs) are a large, diverse group of neurological disorders 
(SPG1-71) with the unifying feature of prominent lower extremity spasticity, due to a length-
dependent axonopathy of corticospinal motor neurons.  The most common early-onset form of 
pure, autosomal dominant HSP is caused by mutation in the ATL1 gene encoding the atlastin-1 
GTPase, which mediates homotypic fusion of ER tubules to form the polygonal ER network.  
Here we have identified a p.Pro342Ser mutation in a young girl with pure SPG3A. This residue 
is in a critical hinge region of atlastin-1 between its GTPase and assembly domains, and it is 
conserved in all known eukaryotic atlastin orthologs.  We produced induced pluripotent stem 
cells (iPSCs) from skin fibroblasts and differentiated these into forebrain neurons to generate a 
human neuronal model for SPG3A.  Axons in these SPG3A neurons showed impaired growth, 
recapitulating axonal defects in atlastin-1-depleted rat cortical neurons and impaired root hair 
growth in loss-of-function mutants of the ATL1 ortholog rhd3 in the plant Arabidopsis.  Both the 
microtubule cytoskeleton and tubular ER are important for mitochondrial distribution and 
function within cells, and SPG3A neurons showed alterations in mitochondrial motility.  Even so, 
it is not clear whether this change is involved in disease pathogenesis.  The SPG3A axon 
growth defects could be rescued with microtubule-binding agents, emphasizing the importance 
of tubular ER interactions with the microtubule cytoskeleton in HSP pathogenesis.  The 
prominent alterations in axon growth in SPG3A neurons may represent a particularly attractive 
target for suppression in screens for novel pharmacologic agents.     
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4.2 Introduction 
Hereditary spastic paraplegias are a diverse group of inherited neurological disorders unified by 
the defining feature of a length-dependent axonopathy of corticospinal motor neurons, resulting 
in prominent lower extremity spasticity and gait difficulties [54, 201].  These disorders were 
historically classified as pure or complex based upon the presence (complex) or absence (pure) 
of associated clinical features such as cognitive impairment, distal amyotrophy, retinopathy, 
neuropathy, and thin corpus callosum.  More recently, a genetic classification scheme has 
predominated, and HSPs are commonly identified by their affected genes and spastic gait 
(SPG) loci, SPG1-71, assigned in order of locus identification [18, 54, 201, 202].  Despite the 
remarkable genetic heterogeneity of HSPs, a relatively small number of common cellular 
themes have emerged, including perturbations in mitochondrial function, endoplasmic reticulum 
shaping/distribution, myelination, lipid/cholesterol metabolism, nucleotide metabolism, 
protein/membrane trafficking, bone morphogenetic protein (BMP) signaling, and endolysosomal 
function [1, 18, 202]. 
Disruption in the formation of the tubular ER network in cells has emerged as a key 
pathogenic theme underlying the HSPs, since over half of patients with autosomal dominant, 
pure HSP have SPG3A, SPG4, SPG12, or SPG31, each of which is caused by mutations in 
genes encoding proteins that bind one another and function in the organization of the tubular 
ER network [1, 54, 203].  Thus, the development of animal and cellular models for these 
disorders of ER network formation is increasingly important. 
The SPG3A protein atlastin-1 along with its human paralogs atlastin-2 and atlastin-3, 
yeast ortholog Sey1p, and plant ortholog RHD3 are large, oligomeric GTPases that harbor two 
very closely-spaced transmembrane domains required for proper ER localization; these 
GTPases mediate homotypic fusion of ER tubules to form the polygonal ER network [71, 72, 
204-208].  The SPG31 and SPG12 proteins REEP1 and reticulon-2, respectively, are members 
of the reticulon/REEP/Yop1p superfamily of proteins that harbor partially-membrane spanning, 
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hydrophobic hairpin domains and shape the high-curvature ER tubules [209, 210].  Last, the 
SPG4 protein spastin is an ATPase associated with a variety of activities (AAA), and the larger 
M1 spastin isoform harbors a hydrophobic hairpin and localizes to ER tubules.  These 
hydrophobic domains are important for self-interactions among these proteins as well as for 
interactions with one another [69].   
To date no mouse model has been reported for SPG3A, the second most common 
cause of HSP and the most common early-onset form; there have been a few cellular as well as 
fly and zebrafish models described.  For instance, depletion of atlastin-1 in rat cortical neurons 
in primary culture using shRNA causes prominent axon growth and branching defects [211].  
Disruption of the single atlastin ortholog in Drosophila causes synapse and muscle defects that 
can be rescued with the microtubule-destabilizing drug vinblastine [22], indicating the 
importance of interactions among ER shaping and microtubule-interacting proteins [22].  In 
zebrafish, knockdown of the atlastin gene atl1 causes a decrease in larval mobility that is 
preceded by abnormal architecture of spinal motor axons [20]. 
Here, we have identified a novel de novo SPG3A mutation (c.1024C>T; p.Pro342Ser) in 
a 2-year old girl with early-onset, pure HSP.  This Pro residue is at a critical position for atlastin-
1 within a small linker region between the GTPase domain and three-helical bundle (3HB) 
assembly domain.  In fact, this Pro residue is conserved in all eukaryotic atlastin orthologs [212].  
We used skin fibroblasts from this patient to generate induced pluripotent stem cells (iPSCs), 
which were then differentiated into forebrain neurons to generate the first human neuronal 
model of SPG3A.  These neurons have prominent axonal growth defects that can be partially 
rescued with microtubule-binding agents, emphasizing the importance of interactions of tubular 
ER with the microtubule cytoskeleton in HSP pathogenesis [69].   
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4.3 Results 
4.3.1 Cellular effects of SPG3A ATL1 mutation 
A 2 year-old girl with a clinical presentation of early-onset, pure HSP had a de novo, 
heterozygous mutation in ATL1, c.1024C>T (p.Pro342Ser), identified by commercial DNA 
sequencing (Athena Diagnostics).  Though this mutation has not been previously reported, it 
occurs at a residue mutated in other patients with SPG3A [213], and is conserved among all 
eukaryotes in the linker region of atlastin GTPases (Fig. 4-1A); this linker plays a key role in a 
conformational switch of atlastin important for the ER tubule fusion process (Fig. 4-1B; [212, 
214]).  This mutation also results in a modest reduction in GTPase activity (Fig. 4-1C-D).   
Skin fibroblasts were cultured to assess the effects of this mutation on atlastin-1 protein 
levels.  Immunoblots of SPG3A and control fibroblast cultures indicate that levels of the atlastin-
1 protein are not diminished in the mutant cells, suggesting that the mutant protein is present in 
cells.  Levels of a number of other ER proteins, including the atlastin-1 paralogs atlastin-2 and 
atlastin-3, which are abundant in these cells [207], are also not significantly affected (Fig. 4-2A).  
The atlastin-1 P342S protein is also present in puncta throughout the peripheral ER, which is 
mostly tubular ER in contrast to the more perinuclear ER sheets labeled with CLIMP-63 (Fig. 4-
2B). The distributions of endogenous atlastin-1 positive puncta appeared similar in control and 
atlastin-1 P342S fibroblasts (Fig. 4-2C).  Since atlastin-2 and -3 are likely the predominant 
atlastin proteins in skin fibroblasts and may thus provide adequate protein for ER fusion even in 
the presence of atlastin-1 dysfunction, we examined effects of atlastin-1 P342S overexpression 
in these cells.  Heterologous expression of  Myc-tagged, wild-type atlastin in COS7 cells did not 
result in changes in ER morphology, but expression of the P342S mutant markedly altered ER 
morphology in all cells examined (Fig. 4-2D). 
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Figure 4-1. Atlastin-1 P342S SPG3A mutation affects a critical residue for conformational shifts, 
and alters GTPase activity.  (A) Schematic diagram of atlastin-1 domain organization (top) and 
sequence comparisons among different species in the atlastin-1 linker region (bottom). 
Asterisks (*) denote conserved residues, and the conserved Pro342 residue is shown in red. 
Abbreviations:  3HB, three helical bundle; TM, transmembrane domains.  (B) Left, superposition 
of the cytosolic domain of atlastin-1 in two different crystal forms, denoted 1 and 2, with the 
respective GTPase domains as the reference. Right, Major differences in conformation that 
comprise a GTPase domain-internal helix and position of the 3HB domain accompanied by 
restructuring of the linker region with the different positions of Pro342 shown. This image with 
labels modified slightly is reproduced with permission from Sondermann and Byrnes [212].  (C 
and D) Myc-tagged wild-type atlastin-1 or the P342 missense mutant were immunopurified from 
COS7 cells, and GTP hydrolysis was performed in vitro and plotted as a function of time (C). 
Representative thin-layer chromatography plates show conversion of GTP to GDP (D). Means ± 
SD are graphed.   
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4.3.2 Characterization and neural differentiation of control and SPG3A iPSCs 
SPG3A iPSCs were generated from skin fibroblasts cultured from the patient with this 
P342S mutation in atlastin-1.  The fibroblasts were reprogrammed using an integration-free 
episomal method [156], and multiple iPSC clones were generated from both the SPG3A 
fibroblasts and wild-type controls.  These clones had a typical ESC colony morphology, with no 
obvious differences between SPG3A and control lines, and expressed the characteristic human 
PSC markers Nanog, SSEA4 and Tra1-60 (Fig. 4-3A).  To confirm that the SPG3A iPSCs did 
not contain any chromosomal abnormalities after passaging, karyotype analysis was performed; 
this did not reveal any defects (Fig. 4-3B).  To confirm the presence of the heterozygous 
p.Pro342Ser mutation in the ATL1 gene, this region was sequenced in both the iPSCs and the 
neural cells after differentiation (Fig. 4-3C). 
 
We differentiated the iPSCs to forebrain glutamatergic neurons using a well-established 
differentiation protocol [128, 172, 173].  Representative images are shown for cells at different 
stages during the differentiation (Fig. 4-4A).  No apparent alterations were observed in the 
abilities of control and SPG3A cells to generate neurons.  Although atlastins are expressed in all 
eukaryotic cells, atlastin-1 is by far the most abundant member in the central nervous system 
[71, 207, 211].  To examine how atlastin-1 levels in human neurons change during the course of 
in vitro differentiation, we performed immunoblot analysis (Fig. 4-4B).  Very low levels of 
atlastin-1 protein were present in iPSCs, but by the neurosphere stage at day 28 of 
differentiation there was a dramatic increase.  Atlastin-1 levels remained high in early generated 
neurons (week 6) and in more mature neurons (week 15).  Conversely, levels of atlastin-2 and 
atlastin-3 were high at the iPSC stage, and decreased dramatically following neural 
differentiation (Fig. 4-4C).  Levels of atlastin-1 were comparable between controls and SPG3A 
lines in week 8 neurons (Fig. 4-4D).  Thus, similar to what was observed in patient fibroblasts 
(Fig. 4-2A), the
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Figure 4-2. Atlastin P342S localizes to the tubular ER and disrupts ER morphology.  (A) 
Aliquots of total membranes (10 μg protein per lane) from control or SPG3A P342S human 
fibroblasts were immunblotted for the indicated ER proteins. Sizes of molecular weight 
standards (in kDa) are at the left.  (B) Fibroblasts were co-immunostained for endogenous 
atlastin-1 (green) and CLIMP-63 (red).  (C) Control or SPG3A P342S human fibroblasts were 
co-immunostained for atlastin-1 (green) and calreticulin (red).  (D) COS7 cells were transfected 
with Myc-tagged wild-type or P342S mutant atlastin-1 and immunostained for Myc-epitope 
(green) and β-tubulin (red).  Scale bars: 10 μm in panel B and 20 μm in panels C and D.  
 
 
 75  
 
Figure 4-3.  Generation of SPG3A iPSC lines.  (A) Control and SPG3A iPSC lines expressed 
the human ESC markers Tra-1-60 (red), Nanog (red) and SSEA-4 (green), as visualized by 
immunofluorescence microscopy. Hoechst nuclear staining is blue. Scale bars: 100 µm.  (B) 
SPG3A iPSC lines maintained a normal 46,XX female karyotype after 10 passages as shown by 
G-banded analysis.  (C) DNA sequencing electropherograms confirm the presence of a 
heterozygous c.1024C>T, p.Pro342Ser mutation before and after neural differentiation.  
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p.Pro342Ser mutation did not affect total atlastin-1 protein levels.  In addition, levels of the 
microtubule-severing ATPase spastin, a direct binding partner of atlastin-1 [215, 216] mutated in 
the SPG4 subtype of HSP [55], were not dramatically different between control and SPG3A 
neurons (Fig. 4-4E).  To confirm that forebrain glutamatergic neurons were generated, 
immunostaining was performed for Tbr1 and the neuron-specific tubulin isoform βIII-tubulin (Fig. 
4-4F).  Quantification of Tbr1+ cells did not reveal significant differences between control and 
SPG3A iPSC lines (Fig. 4-4G). 
 
4.3.3 Axonal outgrowth of neurons derived from control and SPG3A iPSCs 
 In a zebrafish model of SPG3A, knocking down atl1 resulted in abnormal axonal 
outgrowth of spinal motor neurons [20].  To investigate axonal morphology in SPG3A iPSC-
derived forebrain neurons, neurospheres were plated onto coverslips and axons were allowed 
to extend for 48 h, then fixed and stained for the axon marker tau.  The tau staining extended to 
the end of the axons, as shown by co-localization with F-actin, which is enriched in growth 
cones (Supplementary Material, Fig. 4-S2).  In addition, the long neurites that extended from 
the neurospheres were established to be axons by the co-localization of tau with the presynaptic 
marker bassoon (Supplementary Material, Fig. 4-S3).  This revealed an apparent reduction in 
the length of axons in the SPG3A axons compared to control neurons (Fig. 4-5A).  
Quantification of neurite outgrowth revealed a significant reduction in the average length of 
axons (Fig. 4-5B).  Analysis of dissociated, singlized neurons revealed a similar reduction in 
axonal outgrowth in SPG3A neurons derived from two different iPSC clones (Fig. 4-6A-B).  
Together these data suggest that SPG3A neurons, have impaired axon outgrowth with reduced 
axon length. 
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Figure 4-4.  Neural differentiation of SPG3A iPSCs.  (A) Representative differential interference 
contrast images of control and SPG3A cells during neural differentiation at various stages. EB, 
embryoid body; NE, neuroepithelia. Scale bars: 100 µm.  (B) Cell aliquots were immunoblotted 
for atlastin-1 during different stages (weeks 0, 4, 6, and 15) of neural differentiation.  Actin levels 
were monitored as a control for protein loading.  (C) Atlastin-2 and -3 levels decrease following 
neural differentiation. Cell aliquots were immunoblotted during different stages (weeks 0, 4, 6, 
and 15) of neural differentiation as shown.  Actin levels were monitored as a control for protein 
loading.  (D) Immunoblot analysis of atlastin-1 protein levels in extracts from week 15 neurons 
derived from wild-type (iWT-1 & iWT-3) and SPG3A iPSCs (iSPG3A-6 & iSPG3A-8). Actin 
levels were monitored as a control for protein loading.  (E) Spastin levels are not dramatically 
altered in SPG3A neurons. Protein samples from week 15 neurons were immunoblotted for 
spastin.  (F) Both control and SPG3A neurons efficiently generated Tbr1+ (red) glutamatergic 
neurons. Nuclei are identified with Hoechst staining (blue), and βIII-tubulin and Tbr1 were 
visualized by confocal immunofluorescence microscopy. Scale bars: 50 µm.  (G) Quantification 
of Tbr1+ neurons did not reveal any significant differences between the indicated iPSC lines. 
Data are presented as means ± SD, n=3. In panels B-E, migrations of molecular mass 
standards in kDa are indicated to the left. 
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Supplementary Figure 1. Tau stains the entire length of axons. (A) Tau staining extends to the 
F-actin enriched growth cones, shown by Rhodamine-Phalloidin staining. (B) Higher 
magnification images of the boxed region in A. Scale bars = 20 µm.  
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Supplementary Figure 2. Axons grow out of neural clusters. (A) Week 8 iWT-1 neural 
aggregates stained for axon markers tau and bassoon. Higher magnification image of the boxed 
region is shown on the right.  (B) Week 8 iSPG3A-6 neural clusters also stained for axon 
markers tau and bassoon. Scale bars = 50 µm. 
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Figure 4-5.  SPG3A neurons display reduced axonal outgrowth.  (A) Fluorescence images of 
Tau+ axons from iPSC-derived neurons two days after plating. Scale bars: 200 µm. (B) 
Quantification of Tau+ axon length shows a significant reduction in SPG3A derived neurons.  
Data are presented as means ± SD, N=3-6 coverslips, with at least 1100 cells analyzed per 
group. **P < 0.01 versus control (iWT-1).   
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Figure 4-6. Reduced axonal outgrowth in singlized SPG3A neurons. (A) Control and SPG3A 
iPSC-derived neurons were plated and cultured for 48 hrs prior to staining for Tau. (B) 
Quantification of mean Tau+ process length for each group. N=3 coverslips, with at least 50 cells 
analyzed per group. Data presented as mean ± SD. *P < 0.05 versus controls.  
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4.3.4 Fast axonal transport defects in SPG3A neurons  
There is abundant evidence that links other forms of dominant, pure HSP to defects in 
fast axonal transport [29, 30, 61, 68, 217].  To investigate whether transport is disrupted in 
SPG3A neurons, we analyzed mitochondrial fast axonal transport in week 12 iPSC-derived 
neurons with live-cell imaging, using the dye MitoTracker CMXRos.  After cells were stained, 
fluorescent images of proximal axons were taken every 5 s for 5 min, and individual trajectories 
for each mitochondrion within the field were acquired, allowing detailed analysis of multiple 
transport parameters.  Representative position versus time kymographs are shown in Fig. 4-7A, 
revealing the nature of fast axonal transport in the two groups.  Comparison of mitochondrial 
transport velocities in both anterograde (Fig. 4-7B) and retrograde (Fig. 4-7C) directions 
revealed no significant differences between control and SPG3A neurons.  The frequency of 
motile events was calculated by counting the number of times each mitochondrion moved with a 
velocity greater than 300 nm/s.  This velocity threshold was used to exclude transport events 
mediated by actin, which fall well below this threshold [133].  Calculation of the percentage of 
motile mitochondria for each cell revealed a significant reduction in SPG3A neurons compared 
to controls (Fig. 4-7D), and the frequency of motile events was lower in the SPG3A neurons as 
compared to controls (Fig. 4-7E).  When these events were separated based on direction of 
transport, while there was only a non-significant trend towards reduction of events in the 
retrograde direction (Fig. 4-7F), a significant reduction in anterograde motile events was 
observed in SPG3A cells (Fig. 4-7G).  
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Figure 4-7.  Decreased mitochondrial transport in SPG3A neurons.  (A) Representative 
distance versus time kymographs show decreased motile mitochondria. Scale bar: 5 µm. (B and 
C) The velocity of movement events in anterograde (B) and retrograde (C) directions were 
unaffected in SPG3A neurons.  (D) The percentage of motile mitochondria was significantly 
decreased in SPG3A neurons.  (E) The number of motile movement events (velocity >300 
nm/s) was also decreased in SPG3A neurons.  (F and G) There was a non-significant trend 
toward a decreased frequency of motile movement events (per mitochondrion over 5 min) in the 
retrograde direction (F), while the frequency of events in the anterograde direction (G) was 
significantly reduced in SPG3A neurons. Data are presented as means ± SEM, N = 10-20 cells. 
*P < 0.05 versus control group (iWT-1); ns, not significant. 
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4.3.5 Treatment with microtubule-targeting drugs rescues the axon outgrowth phenotype 
In a Drosophila model of SPG3A, where the single atlastin ortholog was disrupted, 
neuromuscular junction defects were linked to abnormal accumulation of stable microtubules 
[22].  It was suggested that this effect of atlastin is mediated through atlastin’s interactions with 
the SPG4 protein spastin, a microtubule-severing AAA ATPase.  Importantly, treatment with the 
microtubule-destabilizing drug vinblastine partially rescued neuromuscular junction defects and 
improved the survival of mutant flies [22].  To test whether treatment with microtubule-targeting 
drugs is similarly effective on human SPG3A neurons, and whether this iPSC-based model will 
have the potential for drug screening, we treated week 8 SPG3A neurons with several 
compounds.  Briefly, both control and SPG3A neural progenitors were plated onto coverslips 
and allowed to attach for 24 h.  The next day, neurons were treated with 10 nM vinblastine for 
48 h, followed by analysis of tau+ axon growth.  While vinblastine treatment did not have a 
significant effect on axon outgrowth in control neurons, it significantly increased outgrowth in the 
SPG3A cells (Fig. 4-8A-B), suggesting that alterations in microtubule dynamics may be 
involved in this phenotype. 
 A previous report investigating a mouse model of SPG4 found that treatment with 
nanomolar concentrations of both vinblastine and taxol, which are thought to alter only 
microtubule dynamic instability at these concentrations, significantly reversed the presence of 
axonal swellings in cortical neurons [167].  Treatment of wild-type iPSC-derived neurons with 
taxol or vinblastine did not alter axon outgrowth significantly.  However, treatment with either 
taxol or vinblastine significantly increased axon outgrowth in the SPG3A cells (Fig. 4-8A-B).  
Together, these results reveal that microtubule-targeting drugs are able to rescue axon 
outgrowth defects in SPG3A patient-iPSC derived neurons. 
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4.4 Discussion 
We have used skin fibroblasts from an SPG3A patient with a novel p.Pro342Ser 
mutation in the ATL1 gene to generate iPSC lines and model this common, early-onset, pure 
form of HSP in human neurons.  The SPG3A iPSCs were able to differentiate into forebrain 
glutamatergic neurons with an efficiency similar to that of control neurons, and levels of atlastin-
1 protein were not decreased by the p.Pro342Ser mutation.  Since overexpression of this 
mutant alters ER morphology in a manner similar to atlastin depletion, a dominant-negative, 
loss-of-function disease mechanism appears most likely, with mutant proteins binding and 
impairing the function of the wild-type protein in atlastin oligomers.  Previously, lymphoblasts 
from a patient with a p.N436del in-frame deletion in ATL1 were shown to have markedly 
decreased atlastin-1 levels, which were postulated to result from increased susceptibility of wild-
type/p.del436N heteromers to degrade in a dominant-negative manner [218].  Very recently, 
multiple affected members of a consanguineous Pakistani family were reported with a 
homozygous p.Arg118Gln mutation in ATL1; heterozygotes had minimal or no clinical signs, 
consistent with recessive inheritance, though the functional effects of this mutation are unknown 
[219].  In these cases, a loss-of-function pathogenesis seems most plausible, while also 
illustrating that loss of atlastin function can arise in a number of ways.  
Consistent with a dominant-negative, loss-of-function disease mechanism, SPG3A 
p.Pro342Ser neurons displayed markedly reduced axonal outgrowth, similar to results from 
shRNA knockdown of rat cortical neurons [211].  This phenotype is also highly similar to that 
seen in loss-of-function mutations in the atlastin-1 ortholog RHD3 of the flowering plant 
Arabidopsis, where there are prominent defects in root hair growth [220].  These root hairs are 
long protrusions from root cells that are reminiscent of axons [54, 221].  Thus, these defects in 
polarized cell expansion are a broadly conserved function of atlastin proteins across phylogeny
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Figure 8.  Vinblastine treatment partially rescued the axonal outgrowth phenotype in SPG3A-
derived neurons.  (A) Immunofluorescence images of control and SPG3A plated neural clusters 
treated with vehicle, 10 nM vinblastine, or 10 nM taxol for 48 h. Scale bars: 100 µm.  (B) 
Quantification of axon length showed that vinblastine and taxol treatment significantly increased 
the length of axons in SPG3A-derived neurons. Data are presented as means ± SD, with a 
minimum of 1100 cells analyzed per group. *P < 0.05 versus controls (iWT-1); #P < 0.05 versus 
vehicle-treated SPG3A group. 
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and consequently may represent an important phenotype for rescue in pharmacologic screens.  
In fact, these axon growth defects in human SPG3A neurons could be rescued by treatment 
with both vinblastine and taxol at nanomolar concentrations, indicating an important role for ER 
interactions with dynamic microtubules. 
In addition to its interactions with microtubules, the ER has extensive interactions with 
other organelles, which could be also impacted by changes in ER shape [222].  We investigated 
fast axonal transport of mitochondria because such defects have already been observed in 
autosomal dominant SPG4 [29, 68, 167], which is caused by mutations in the spastin AAA 
ATPase that binds atlastin-1.  There were no differences in the transport velocities of 
mitochondria in either anterograde or retrograde directions, suggesting that activities of the 
molecular motors were unaffected.  However, there were decreases in the frequency of total 
mitochondrial motile events and events in the anterograde direction, while there was a non-
significant trend towards reduced retrograde events in the SPG3A neurons.  Since the 
axoplasm accounts for >99% of total cellular volume in the longest neurons, they are particularly 
susceptible to defects in intracellular transport [1].  In fact, many neurodegenerative disorders 
have been linked to deficits in axonal transport, including amyotrophic lateral sclerosis (ALS), 
Parkinson disease, Alzheimer disease, and Huntington disease [132].  The proper distribution of 
mitochondria and likely other organelles throughout the axon thus appears critical for 
maintaining neuronal health.   
Defects in axonal transport of mitochondria, other organelles, or proteins may underlie 
the axon outgrowth defect that is observed in these SPG3A cells.  A majority of proteins in the 
axon and at synapses are generated in the cell body and must be transported down axons via 
anterograde transport [143].  Mitochondrial localization, which is dependent on fast axonal 
transport, is also important for regulating the variability of presynaptic strength as well as for 
axon formation and outgrowth [144, 145].  In fact, mitochondria accumulate in the growth cones 
of axons during outgrowth [223].  In the SGP3A neurons, reduction in the number of 
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anterograde motile events could conceivably reduce the net flux of mitochondria towards the 
distal portions of the axons, negatively affecting axon outgrowth, presynaptic regulation, or both.  
However, selectively increasing mitochondrial axonal mobility does not slow ALS-like 
impairment in the SOD1(G93A) mutant mouse model for ALS [224].  Alternatively, other 
consequences of atlastin dysfunction such as aberrant ER distribution (which could secondarily 
affect mitochondrial motility) or BMP signaling [1] may play key roles in pathogenesis. 
Studies in Drosophila have previously shown that there are increased stabilized 
microtubules in atl mutant flies and that vinblastine treatment can rescue several neuromuscular 
defects [22].  Loss of atlastin function was hypothesized to result in altered microtubules by 
disrupting the interaction between atlastin and the microtubule-severing, SPG4 ATPase spastin. 
We and others have previously shown that treatment with microtubule-targeting drugs can 
rescue defects in SPG4 cells in situ, suggesting that altered microtubules may be a common 
finding among different forms of HSP [30, 167, 176].  One role of atlastin-1 may be to distribute 
spastin’s microtubule-severing activity within neurons, since spastin is a direct binding partner 
[69, 215, 216]. Reduced atlastin-1 within the distal portions of axons may affect the function of 
spastin in these regions, resulting in increased stabilized microtubules.  Treatment with sub-
stoichiometric concentrations of either vinblastine or taxol increased axonal outgrowth to levels 
comparable to wild-type neurons.  It will be interesting to examine further whether axon growth 
and transport deficits can be rescued by these drugs in longer-term cultures.   
On initial consideration, it seems hard to reconcile a primary defect in axon growth as a 
mediator or the pathology in HSPs, since most HSPs are progressive disorders characterized 
by  distal, dying-back axonal degeneration [1, 18, 54, 201, 202, 225].  However, SPG3A in 
particular is notable for not only being the most common early-onset, pure form of HSP, but also 
for having a large number of affected individuals presenting with apparently non-progressive 
forms [6].  Thus, abnormal axon development may play a key role in SPG3A pathogenesis.  Our 
findings suggest that iPSC-based models of SPG3A will be useful for drug screening studies.  In 
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future studies, it will be particularly interesting to assess how rescue of axon growth defects due 
to SPG3A mutations correlates with rescue of known intracellular functions of atlastins, such as 
BMP signaling, ER morphology, organelle distribution, and lipid droplet formation [19, 20, 226]. 
 
4.6 Materials and Methods 
4.6.1 Clinical studies 
All study procedures were performed under an Institutional Review Board-approved 
clinical research protocol (NINDS protocol 00-N-0043) at the National Institutes of Health 
Clinical Center.  The parents of the SPG3A patient provided informed consent.   
 
4.6.2 Cell culture, transfection, and GTPase activity assays 
Heterologous expression studies in COS7 cells and in vitro GTPase assays of Myc-
atlastin-1 proteins were performed as described previously [71, 227].  
 
4.6.3 Reprogramming fibroblasts into iPSC lines 
Human fibroblast cell lines were established from skin punch biopsies and maintained 
using standard procedures.  To generate iPSC lines using episomal transduction, ~200,000 
cells were dissociated and transfected with episomal plasmids (Addgene) containing 
pluripotency factors (Oct3/4, Sox2, L-Myc, Klf4, and Lin 28), as reported previously [156].  At 
around one week after electroporation transduction, cells were plated onto a 35-mm dish in 
DMEM supplemented with 10% fetal bovine serum. After culturing for 7 days, cells were 
dissociated and seeded onto a mouse embryonic fibroblast (MEF) feeder at ~105 cells/100-mm 
dish. Two weeks later, colonies with morphologies similar to human embryonic stem cells 
(ESCs) were observed.  These colonies were split onto MEF feeder cells to derive iPSC lines.  
Following several passages, homogenous colonies with ESC-like morphology were generated.  
The iPSC lines used in this study were iWT-1, iWT-3, iSPG3A-6, and iSPG3A-8. 
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4.6.4 Human iPSC neural differentiation 
To generate telencephalic neurons from iPSCs, stem cells were cultured on a feeder 
layer of irradiated MEFs in 6-well tissue culture treated plates for around 6 days, with the human 
ESC media (+10 ng/ml fibroblast growth factor [FGF]-2) changed daily.  When nearly confluent, 
cells were detached from the feeder layer to initiate neural differentiation, as previously 
described [128, 172, 173].  Briefly, iPSC aggregates were cultured in suspension for 4 days in 
human ESC media and were then transferred to neural induction media (NIM).  After 3 
additional days in suspension, iPSC aggregates were plated onto 6-well tissue culture treated 
plates in NIM with 10% fetal bovine serum.  After 12 h, the media was replaced with fresh NIM. 
Media was then changed every other day until day 17, when the generated neuroepithelial (NE) 
cells were isolated.  Mechanically-isolated NE cells were cultured in suspension with NIM 
(+B27, +cyclic AMP, +insulin-like growth factor 1 [IGF-1]) to generate neurospheres for at least 
10 additional days.  On about day 28, neurospheres were dissociated and plated onto 
polyornithine- and laminin-coated coverslips in neural differentiation media containing N2, B27, 
ascorbic acid, cyclic AMP, laminin, IGF-1, brain-derived neurotrophic factor, and glial-derived 
neurotrophic factor.  Half of the media was changed every other day for 6-12 weeks, depending 
on the analysis to be performed.  For treatment of cells with microtubule-targeting drugs, the 
media was replaced with standard neural differentiation media with either 10 nM vinblastine 
(Sigma-Aldrich) or 10 nM taxol dissolved in water. 
 
4.6.5 Immunoblotting and immunocytochemistry 
Confocal immunofluorescence microscopy and immunoblotting were performed as 
described previously [71, 128, 158].  Quantification of immunoblots was performed using 
ImageJ [155], normalized against actin as a loading control.  The percentage of Tbr1+ cells 
among total cells (Hoechst) was determined by taking 3 randomly selected fields per coverslip 
and blindly counting cells using MetaMorph software [128].  Three coverslips were analyzed for 
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each group. 
Antibodies used in this study included: mouse monoclonal IgM anti-Tra-1-60 (Santa 
Cruz, 1:50); goat polyclonal IgG anti-Nanog (R&D Systems, 1:500); mouse monoclonal IgG3 
anti-SSEA-4 (Developmental Studies Hybridoma Bank, 1:100); mouse IgG2b monoclonal anti-
acetylated tubulin (Sigma-Aldrich, 1:10,000); rabbit IgG anti-tau (Sigma-Aldrich, 1:100); rabbit 
polyclonal anti-Tbr1 (Proteintech, 1:1000); mouse monoclonal IgG βIII-tubulin (TuJ-1; 
Developmental Studies Hybridoma Bank, 1:100); rabbit polyclonal anti-REEP5 (Proteintech, 
1:2000), rabbit polyclonal anti-atlastin-1, -2, and -3 [207], rabbit polyclonal anti-calreticulin 
(Abcam, 1:1000),mouse monoclonal Myc-epitope (Santa Cruz Biotechnology, 1:1000), mouse 
monoclonal anti-β-tubulin (Sigma-Aldrich, 1:2000), rabbit polyclonal anti-spastin (Sigma-Aldrich, 
1:1,000).  Rhodamine-phalloidin (100 nM) was from Cytoskeleton. 
 
4.6.6 Axon length measurements 
Axon outgrowth properties of neurons plated in small clusters were quantified with 
MetaMorph software using the Neurite Outgrowth application as described by the manufacturer. 
This program identifies cell bodies and their neurites and determines the length of each neurite.  
Three-to-six coverslips for each group, comprising at least 1100 cells per group, were analyzed 
for neurite outgrowth.  Axonal outgrowth of singlized neurons was quantified using the NeuronJ 
plugin for ImageJ, and the length of the longest process which also had the greatest tau 
intensity was measured.   At least 50 cells were quantified per cell line, for a total of 123 control 
and 175 SPG3A cells from at least 3 coverslips. 
 
4.6.7 Live-cell imaging 
Neurospheres were plated onto polyornithine- and laminin-coated 35 mm dishes 
(MatTek). At 8 weeks of total differentiation, the cells were stained with 50 nM MitoTracker Red 
CMXRos (Invitrogen) for 3 min to allow visualization of mitochondria, after which the media was 
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replaced with fresh neural differentiation media.  Live-cell imaging was performed using a Zeiss 
Axiovert 200M microscope equipped with an incubation chamber.  The cells were kept at 37°C 
with 5% CO2 while imaging.  Axons identified according to morphological criteria (constant thin 
diameter, long neurites, no branching and direct emergence from the cell body) were imaged 
every 5 s for 5 min, yielding 60 frames.  Quantifications were performed using a protocol 
described previously [133].  In short, the location of each mitochondrion was manually selected 
using the Track Points function in MetaMorph, and parameters such as distance from cell body 
and velocity were recorded.  A velocity threshold of 300 nm/s was used to select microtubule 
based transport events [157].  To determine the percentage of motile mitochondria, the total 
number of mitochondria that were present along the imaged neurite was counted, and those 
that changed position (velocity >300 nm/s) in at least 3 consecutive frames were considered 
motile. 
 
4.6.8 Statistical analysis 
The statistical significance in mean values among multiple sample groups was analyzed 
with Turkey’s studentized range test after ANOVA. Two-sided t-tests were used to examine the 
statistical significance between two sample groups.  The significance level was defined as 
P<0.05, and significance tests were conducted using SAS 9.1 (SAS Institute). 
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5.1 Abstract 
Hereditary spastic paraplegias (HSPs) comprise a large and diverse group of inherited 
neurodegenerative disorders (SPG1-71). The hallmark of all HSP subtypes is a length-
dependent distal axonopathy, resulting in prominent lower limb spasticity, which is primarily 
caused by the degeneration of cortical-spinal motor neurons. In addition, with many forms of 
HSP, patients have additional symptoms due the involvement of additional cell-types.  Two 
autosomal recessive forms of HSP, SPG15 and SPG48, are associated with thinning of the 
corpus callosum, cognitive impairment, ataxia, and juvenile parkinsonism. Interestingly, these 
patients respond to L-Dopa treatment, suggesting dopaminergic neuron dysfunction. The 
causative gene for SPG15 is ZFYVE26, which encodes the ubiquitously expressed protein 
spastizin, with particularly high levels in neurons. In SPG48, the adaptor protein complex 5 zeta 
1 (AP5Z1) protein, which was found to bind to spastizin, is lost. These two proteins have been 
shown to be involved in autophagy, cytokinesis, and potentially in axonal transport. However, 
the mechanisms by which the loss of these two proteins results in axonal defects are unknown. 
In this study, we have generated and validated induced pluripotent stem cell (iPSC) lines from 
SPG15 and SPG48 patients along with unaffected siblings and other controls individuals. We 
then differentiated these iPSC lines to telencephalic glutamatergic and midbrain dopaminergic 
(mDA) neurons, both of which are expected to display disease-specific phenotypes. As a 
control, cells were also differentiated into spinal neurons, which are unaffected in patients. 
Control, SPG15, and SPG48 iPSC lines were successfully differentiated into both neuronal 
subtypes using well-established directed differentiation protocols. Interestingly, neurite number, 
length, and branching were significantly reduced in SPG15 and SPG48 telencephalic 
glutamatergic neurons and mDA neurons, suggesting that spastizin and AP5Z1 play a role in 
neurite development. Next, the morphology of mitochondria was analyzed, as spastizin has 
been shown to partially localize to the mitochondrial membrane. This revealed a significant 
reduction in the length and density of mitochondria within neurites of SPG15 and SPG48 
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telencephalic glutamatergic neurons and mDA neurons. Mitochondrial membrane potential was 
reduced in SPG15 neurons, and there was an increase in apoptosis in both SPG15 and SPG48 
cells. Treatment with the Drp1 inhibitor, mdivi-1, rescued mitochondrial morphology, neurite 
outgrowth, and levels of apoptosis in SPG15 neurons. These results link mitochondrial 
fission/fusion alterations to SPG15 and SPG48, and identify mitochondria as a potential target 
for therapeutics in the future.  
 
5.2 Introduction 
Hereditary spastic paraplegias (HSP) are a heterogeneous group of 71 genetic disorders 
that result in progressive lower limb spasticity due to a length-dependent degeneration of the 
corticospinal motor neuron (CSMN) axons [1, 18]. SPG11, SPG15, SPG48 comprise a 
subgroup of 3 complex recessive forms that have predominantly overlapping phenotypes, 
including thinning of the corpus callosum, cognitive impairments, and occasionally parkinsonism 
[228]. The onset of symptoms is mainly during the first two decades of a patient’s life [36]. 
Interestingly, the gene products affected in these three HSP subtypes can directly interact with 
each other [83]. SPG11 is the most common, and SPG15 is the second most common 
recessive HSP subtype associated with thin corpus callosum [229]. The causative gene for 
SPG15 is ZFYVE26, which encodes the ubiquitously expressed ~280 kD protein spastizin, with 
particularly high levels in neurons [80, 230, 231]. Spastizin harbors a zinc-finger/FYVE domain 
that is thought to allow it to interact with phosphoinositide-3 phosphate (PI3P) [232]. Spastizin 
localizes to a number of regions within cells, including the cytoplasm, endoplasmic reticulum, 
microtubules and mitochondria [230]. The precise role of spastizin within cells, particularly 
neurons, remains unclear. Spastizin has been suggested to be involved in axonal outgrowth and 
targeting in zebrafish [91], autophagy [92], cytokinesis [95, 96], and potentially in axonal 
transport [81]. SPG48 is the result of mutations to the AP5Z1 gene, which encodes the adaptor 
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protein complex ζ subunit (AP5Z1) [84]. AP5Z1 is a subunit of the common heterotetrameric 
adaptor protein complex 5 (AP-5), an evolutionarily conserved complex thought to be involved in 
endosomal dynamics, although its precise localization and function are still unclear [85]. Adaptor 
proteins (APs) are a family of 5 related protein complexes, with AP-5 being the most recently 
discovered [86]. AP-1 and AP-2 are the most well-characterized, and have been shown to 
promote clathrin  assembly in vitro by providing a bride between clathrin and membranes [87]. 
APs are comprised of 5 subunits, β1-5, one of either α, γ, δ, ε, or ζ, and μ1-5, and σ1-5 [85]. In 
addition to AP5Z1, mutations to the AP-4 subunit AP4E1 were shown in 2011 to result in an 
autosomal recessive form of HSP, SPG51 [88].  
 
SPG15 and the related SPG11 can also present with juvenile onset parkinsonism, which 
shows significant improvement following dopaminergic therapy [62, 90]. This suggests that in 
addition to CSMNs, mDA neurons are sensitive to spastizin levels. To date, examination of mDA 
neurons lacking spastizin or AP5Z1 has not been reported.  
 
Mitochondria are highly dynamic organelles that serve as the main source for ATP. 
Mitochondrial dysfunction has been implicated in a wide variety of developmental and 
degenerative neurological disorders. Neurons are highly dependent on mitochondria because of 
their limited glycolytic capacity [233]. While there are only two HSP genes that encode 
mitochondrial proteins, paraplegin and HSP60, there are several HSP subtypes associated with 
mitochondrial trafficking disturbances. In SPG4 and SPG3A, decreased fast axonal transport of 
mitochondria is observed [24, 30, 62, 68].  
 
Mitochondrial shape and size are determined by a delicate balance between fusion and 
fission forces. Fusion proteins include mitofusin-1, mitofusin-2, and optic atrophy protein 1 
(Opa1), while dynamin-related protein 1 (Drp1) is the main fission protein. The proper 
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maintenance of mitochondrial morphology is very important for neuronal health, as a variety of 
neurodegenerative diseases are caused by mutations in genes encoding fission/fusion proteins 
[234].  Although previously, spastizin has been shown to partially colocalize with mitochondria 
[82], the contribution of spastizin and AP5Z1 to mitochondrial health has not been examined. 
 
Here, we sought to examine SPG15 and SPG48 using human pluripotent stem cells 
(hPSCs), including patient-specific induced pluripotent stem cells (iPSCs) and knockdown 
human embryonic stem cells (hESCs). These cells were differentiated into several neuronal 
subtypes so that effect of spastizin and AP5Z1 loss could be examined in human neurons with 
the patient’s genetic background. This revealed cell-type specific defects in neurite projection, 
apoptosis, mitochondrial morphology and membrane potential. Lastly, these cells were used to 
test therapeutic agents. The mitochondrial fission inhibitor mdivi-1 was effective at rescuing 
neurite outgrowth and apoptosis in telencephalic glutamatergic SPG15 neurons, suggesting 
mitochondrial dynamics may be a potential therapeutic target in the future. 
 
5.3 Materials and methods 
5.3.1 Clinical studies 
All study procedures were performed under an Institutional Review Board-approved 
clinical research protocol (NINDS protocol 00-N-0043) at the National Institutes of Health 
Clinical Center.  The SPG15 patient was a 26 year old woman who developed spastic 
paraparesis around the age of 20. In addition she has developed dysarthria, cognitive decline, 
fine action tremor, and she is no longer able to work. Magnetic resonance imaging (MRI) 
identified significant thinning of the corpus callosum.  
 
 
 
 98  
5.3.2 Reprogramming fibroblasts into iPSC lines  
Human fibroblast cell lines were established from skin punch biopsies and maintained 
using standard procedures.  To generate iPSC lines using episomal transduction, ~200,000 
cells were dissociated and transfected with episomal plasmids (Addgene) containing 
pluripotency factors (Oct3/4, Sox2, L-Myc, Klf4, and Lin 28), as reported previously (22).  At 
around one week after electroporation transduction, cells were plated onto a 35-mm dish in 
DMEM supplemented with 10% fetal bovine serum.  After culturing for 7 days, cells were 
dissociated and seeded onto a mouse embryonic fibroblast (MEF) feeder at ~105 cells/100-mm 
dish.  Two weeks later, colonies with morphologies similar to human embryonic stem cells 
(ESCs) were observed.  These colonies were split onto MEF feeder cells to derive iPSC lines.  
After several passages, homogenous colonies with ESC-like morphology were generated.  The 
iPSC lines used in this study were iWT-1, iWT-2, iWT-Sib, iSPG15-1, iSPG15-2, iSPG48-1, and 
iSPG48-2. 
 
5.3.3 Lentivirus production and transduction of hESCs.  
To knock down spastizin and AP5Z1, shRNAs were cloned into pLVTHM. To produce 
high-titer lentivirus, 10 µg of pLVTHM-shRNA lentiviral transfer vector, 7.5 µg of lentiviral vector 
psPAX2, and 5 µg of pMD2.G (VSV-G envelope protein) were cotransfected to HEK293FT cells 
(Invitrogen) using the calcium phosphate method. Sixty hours after transfection, cell culture 
medium containing viral particles were collected and filtered through a 0.45-µm filter (Millipore). 
The viral particles were further concentrated by ultracentrifugation (SW 28 rotor, Beckman) at 
50,000 g for 2 h. The pellet was resuspended in the hESC medium. For transduction of ESCs, 
hESCs were normally passaged and pelleted by brief centrifugation. Cell pellets were then 
incubated with 100 µl of concentrated virus (106 transducing units/ml) at 37°C for 30 min. The 
virus and cell mixture was then transferred to a MEF feeder layer overnight before changing 
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medium on the next day. G418 was used to select transfected cells. The knockdown hESC lines 
were expanded and then differentiated into telencephalic progenitors as described below. 
 
5.3.4 Human iPSC forebrain neuron differentiation 
To generate telencephalic neurons from iPSCs, stem cells were cultured on a feeder 
layer of irradiated MEFs in 6-well tissue culture-treated plates for around 6 days, with the human 
ESC media (+10 ng/ml fibroblast growth factor [FGF]-2) changed daily. When nearly confluent, 
cells were detached from the feeder layer to initiate neural differentiation, as previously 
described (23-25).  Briefly, iPSC aggregates were cultured in suspension for 4 days in human 
ESC media and were then transferred to neural induction media (NIM).  After 3 additional days 
in suspension, iPSC aggregates were plated onto 6-well tissue culture treated plates in NIM with 
10% fetal bovine serum.  After 12 h, the media was replaced with fresh NIM.  Media was then 
changed every other day until day 17, when the generated neuroepithelial (NE) cells were 
isolated.  Mechanically-isolated NE cells were cultured in suspension with NIM (+B27, +cyclic 
AMP, +insulin-like growth factor 1 [IGF-1]) to generate neurospheres for at least 10 additional 
days.  On about day 28, neurospheres were dissociated and plated onto polyornithine- and 
laminin-coated coverslips in neural differentiation media containing N2, B27, ascorbic acid, 
cyclic AMP, laminin, IGF1, brain-derived neurotrophic factor, and glial-derived neurotrophic 
factor.  Half of the media was changed every other day for 6 to 12 weeks, depending on the 
analysis to be performed.  For treatment of cells with mdivi-1, the media was replaced with 
standard neural differentiation media with 10 µM mdivi-1 (Sigma-Aldrich) dissolved in DMSO. 
 
5.3.5 Spinal neuron differentiation: 
The procedure for generating neuroepithelial cells and spinal motor neurons from hESCs 
was essentially the same as described [110, 113]. Briefly, hESCs were induced to neural 
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lineage by forming ESC aggregations and then culturing in neural medium. The early NE cells 
were formed around 8-10 days after differentiation from hESCs, which exhibited columnar 
morphology and started to organize into a rosette-like structure. Human ESC-derived NE cells 
at day 10 were then treated with RA (0.1 μM) for caudalization in a neural medium, which 
consisted of DMEM/F-12 medium, N2 supplement, and heparin. One week later (day 17), the 
posteriorized NE cells were isolated. For specifying spinal motor neurons, these NE clusters 
were suspended in the same neural medium supplemented with B27, RA and purmorphamine. 
To generate forebrain neurons, the neuroepithelial cells were cultured in basic neural medium 
without any caudalizing factors (RA, basic fibroblast growth factor) [128]. These rostral NE cells 
were also isolated at day 17 and suspended in the same neural medium with B27. For terminal 
differentiation, the neural progenitor-enriched clusters were plated onto ornithine/laminin-coated 
coverslips in Neurobasal medium (Invitrogen) supplemented with N2 and B27. 
5.3.6 mDA neuron differentiation: 
mDA neurons were generated following a previously described protocol [160]. In short, 
hPSCs were treated using a similar protocol as the telencephalic glutamatergic neuron 
differentiation, with the addition of several morphogens. From days 10-21, 3µM CHIR99021 was 
included in the NIM. From days 12-23, 2µM purmorphamine was added to the NIM. From days 
21-35, 200ng/ml FGF8 was included in the NIM and NDM. Lastly, starting on day 23 10ng/ml 
sonic hedgehog (SHH) was included in the NIM and NDM.   
 
5.3.7 Immunoblotting and immunocytochemistry 
Confocal immunofluorescence microscopy and immunoblotting were performed as 
described previously [71, 128, 158].  Quantification of immunoblots was performed using 
ImageJ [155], normalized against actin as a loading control  The percentage of TBR1+ cells 
among total cells (Hoechst) was determined by taking 3 randomly selected fields per coverslip 
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and blindly counted using MetaMorph software as we described before [128]. Three coverslips 
were analyzed for each group. 
Antibodies used in this study included: mouse monoclonal IgM anti-Tra-1-60 (Santa 
Cruz, 1:50); goat polyclonal IgG anti-Nanog (R&D Systems, 1:500); mouse monoclonal IgG3 
anti-SSEA-4 (Developmental Studies Hybridoma Bank, 1:100); mouse IgG2b monoclonal anti-
acetylated tubulin (Sigma-Aldrich, 1:10,000); rabbit IgG anti-tau (Sigma-Aldrich, 1:100); rabbit 
polyclonal anti-Tbr1 (Proteintech, 1:1000); mouse monoclonal IgG βIII-tubulin (TuJ-1; 
Developmental Studies Hybridoma Bank, 1:100);  mouse monoclonal anti-β-tubulin (Sigma-
Aldrich, 1:2000) rabbit monoclonal anti-tyrosine hydroxylase (Pel-Freez, 1:400), rabbit 
monoclonal anti-Hoxb4 (Abcam, 1:400). 
 
5.3.8 Neurite outgrowth measurements 
Axonal outgrowth was quantified using the NeuronJ plugin for ImageJ.  Here the length 
of the longest process which also had the greatest tau intensity was measured.  A minimum of 
50 cells were quantified per line, from at least 3 coverslips. 
 
5.3.9 Live-cell imaging 
Neurospheres were plated onto polyornithine and laminin coated 35 mm dishes 
(MatTek).  At 8 weeks of total differentiation, the cells were stained with 50 nM MitoTracker Red 
CMXRos (Invitrogen) for 3 min to allow visualization of mitochondria, after which the media was 
replaced with fresh neural differentiation media.  Live-cell imaging was performed using a Zeiss 
Axiovert 200M microscope equipped with an incubation chamber.  The cells were kept at 37°C 
with 5% CO2 while imaging.  Axons identified according to morphological criteria (constant thin 
diameter, long neurites, no branching and direct emergence from the cell body) were imaged 
every 5 s for 5 min, yielding 60 frames.  Quantifications were performed using a protocol 
described previously (28).  In short, the location of each mitochondrion was manually selected 
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using the Track Points function in MetaMorph, and parameters such as distance from cell body 
and velocity were recorded.  A velocity threshold of 300 nm/s was used to select microtubule 
based transport events (29).  To determine the percentage of motile mitochondria, the total 
number of mitochondria that were present along the imaged neurite was counted, and those 
that changed position (velocity >300 nm/s) in at least 3 consecutive frames were considered 
motile. 
 
5.3.10 Mitochondrial morphology 
Neuronal cultures on glass-bottom 35mm dishes were stained with 25nM MitoTracker 
CMXRos in neural differentiation media for 2 minutes at 37°C. The cells were washed twice with 
fresh NDM, and 2 ml NDM were added to the dish. Live-cell imaging was performed using a 
Zeiss Axiovert 200M microscope equipped with an incubation chamber.  The cells were kept at 
37°C with 5% CO2 while imaging.  Axons identified according to morphological criteria (constant 
thin diameter, long neurites, no branching and direct emergence from the cell body) were 
imaged using a Plan-Apochromat 63x/1.40 Oil DIC objective, with identical microscope settings 
for each group. The 16-bit greyscale images were thresholded in ImageJ and the particle 
analysis function was used to measure morphological characteristics. 
 
5.3.11 Measurement of mitochondrial membrane potential 
Mitochondrial membrane potential was measured based on a previous protocol [235].  
Neurons were plated on 35mm glass-bottomed dishes. The fluorescent dye 
tetramethylrhodamine methyl ester (TMRM, Invitrogen) was used because it accumulates in 
mitochondria based on Δψm. Cells were washed three times with 5mM K
+, 2mM Ca2+ Tyrodes 
solution, then incubated with 10nM TMRM in 2 ml Tyrodes solution for 45 min at room 
temperature in the dark. Live-cell imaging was performed using a Zeiss Axiovert 200M 
microscope equipped with an incubation chamber, using an EC Plan-Neofluar 40x/1.30 Oil DIC 
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objective.  The cells were kept at 37°C with 5% CO2 while imaging. Microscope settings were 
optimized using control cells, and these settings were used for all other groups. Randomly 
selected fields were imaged every 20 s for a total of 600 s. The mitochondrial uncoupler FCCP 
was added to the media after 300 s so that the final concentration was 1µM. The time-series 
were analyzed in MetaMorph and at least 20 regions of interest (ROIs) were traced around 
mitochondrial structures for each cell, along with adjacent background regions. The pixel 
intensity for each region was determined followed by background subtraction. Change in 
fluorescence was calculated with the formula ΔF=F-F0/F0x100, where F is the fluorescence 
intensity at any time point, and F0 is the initial fluorescence. 
 
5.3.12 Caspase 3/7 activity 
For measurements of the activities of caspases 3 and 7, the Caspase-Glo 3/7 Assay 
(Promega) was carried out according to the manufacturer's instructions. Briefly, motor neuron 
progenitor-enriched cultures were dissociated with Accutase (Invitrogen) and seeded into 96-
well plates at 5 000 cells/well in 50 μl of caspase-3/7 reagent. After incubation for 1 h at room 
temperature, luminescence from each well was then measured using Wallac Victor2 1420 
MultiLabel Counter. 
 
5.3.13 Statistical analysis  
The statistical significance in mean values among multiple sample groups was analyzed 
with Turkey’s studentized range test after ANOVA. Two-sided t-tests were used to examine the 
statistical significance between two sample groups.  The significance level was defined as 
P<0.05, and significance tests were conducted using SAS 9.1 (SAS Institute). 
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5.4 Results 
5.4.1 Generation and characterization of SPG15 and SPG48 iPSC lines 
Dermal fibroblasts (Supp. Fig. 5-1A) were transfected with episomal vectors containing 
Oct3/4, Klf4, c-Myc, Lin28, and Nanog [156]. The emergent iPSC colonies were expanded for 
each group and the best clones were used for further analysis. The presence of mutations in the 
fyve-cent gene was confirmed by Sanger sequences in the iSPG15-1 lines (Supp. Fig. 5-2B). 
These mutations were not present in an unaffected sibling of the SPG15 patient, providing a 
control line that shares some genetic background. A homozygous premature stop codon in exon 
15 of the AP5Z1 gene was confirmed in the iSPG48-1 iPSC line (Supp. Fig. 5-1C). The 
generated SPG15 and SPG48 iPSC lines had typical hESC-like colony morphology (Supp. Fig. 
5-1D). In addition, the SPG15 and SPG48 iPSCs expressed typical pluripotent stem cell 
markers, including Nanog, SSEA-4, and Tra-1-60 (Supp. Fig. 5-1E). The fibroblasts from the 
SPG15 patient and unaffected sibling were previously examined, and were found to lack 
spastizin expression at the mRNA and protein level [94]. A significant reduction in fyve-cent and 
AP5Z1 mRNA transcript was observed in SPG15 and SPG48 iPSC-derived neurons (Supp. 
Fig. 5-2A&B). 
 
5.4.2 Neurite outgrowth defects in SPG15 and SPG48 iPSC-derived neurons  
In order to study the effects of lost spastizin and AP5Z1 expression in cell types that are 
clinically relevant, the iPSC lines were differentiated to telencephalic glutamatergic neurons 
[128, 172, 173], spinal neurons [110, 127], and midbrain dopaminergic (mDA) neurons [160] 
using well-established protocols. The differentiation efficiency was determined by examining the 
percentage of cells expressing markers for telencephalic glutamatergic neurons (Tbr1+), spinal 
neurons (Hoxb4+), and mDA neurons (tyrosine hydroxylase, TH+). No significant difference 
between groups in generating these three neuronal subtypes (Fig. 5-1A-D). This data suggests 
that the absence of spastizin and AP5Z1 does not affect neuronal specification. The ability of 
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Figure 5-1: SPG15 and SPG48 iPSCs exhibit normal neuronal differentiation. (A) 
Immunofluorescence images of week 6 telencephalic, spinal, and mDA neurons. Cells were 
stained for acetylated tubulin to label neurites, along with the telencephalic glutamatergic 
marker Tbr1, spinal neuron marker Hoxb4, or the dopaminergic marker tyrosine hydroxylase 
(TH). Scale bar: 20µm. (B) Quantification of the percentage of Tbrl+ neurons. (C) Quantification 
of Hoxb4+ spinal neurons. (D) Quantification of TH+ dopaminergic neurons. Data presented as 
mean ± SEM. 
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Figure 5-2: SPG15 and SPG48 neurons display altered neurite outgrowth. (A) 
Quantification of week 6 neurite outgrowth parameters, including average axon length (longest 
neurite), average length of all primary neurites, and average number of primary neurites in Tbr1+ 
neurons 48 hr after plating. (B) Hoxb4+ neurite outgrowth quantification. (C) TH+ neurite 
outgrowth quantification. All data presented as mean ± SEM. *P< 0.05 compared to iWT-1. #P< 
0.05 compared to iWT-sibling cells.   
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these neurons to project neurites was then examined and compared between neuronal subtype 
(Fig. 5-2A-C). Interestingly, the length of the longest neurite, which generally develops into the 
axon, was significantly reduced in the SPG15 and SPG48 Tbr1+ and TH+ neurons, but not the 
Hoxb4+ neurons. The average length of primary neurites was also reduced in Tbr1+ SPG15 and 
SPG48 neurons, and in TH+ SPG48 neurons. Lastly, the number of primary neurites was 
reduced in SPG15 and SPG48 Tbr1+ neurons.  Analysis of neurite outgrowth was repeated on 
additional clones, and again, SPG15 and SPG48 neurons had reduced outgrowth in 
telencephalic glutamatergic neuron cultures (Supp. Fig. 5-3).  This data suggests that neurite 
outgrowth in telencephalic neurons and mDA neurons is sensitive to the levels of spastizin and 
AP5Z1, while spinal neurons are not.  
 
A hallmark pathological change found in various HSP subtypes is the presence of 
enlarged, swollen axons [30, 68, 236]. To examine if swellings are present in week 6 SPG15 
and SPG48 iPSC-derived telencephalic glutamatergic neurons were stained for acetylated 
tubulin. While there were almost no swellings in control lines, there was a significant increase in 
the SPG15 and SPG48 neurons (Fig. 5-3A&B).  
 
5.4.3 Loss of Spastizin and AP5Z1 alters mitochondrial morphology and function 
Previously it has been shown that spatizin partially localizes to mitochondria [82], 
therefore we examined mitochondrial morphology in the two affected neuronal subtypes. 
Telencephalic glutamatergic and mDA neuron cultures were stained with MitoTracker CMXRos, 
and live-cell images were taken of primary neurites. This revealed a significant reduction in 
mitochondrial length in SPG15 and SPG48 telencephalic glutamatergic neurons (Fig. 5-4A&B). 
There was also a reduction in aspect ratio (length/width) in the SPG15 neurons (Fig. 5-4C). In 
addition to the size change, there was a significant reduction in the number of mitochondria per 
1µm neurite for the SPG48 neurons (Fig. 5-4D), and a reduction in linear density for both 
groups (Fig. 5-4E). Neurons in the mDA cultures also showed changes to mitochondrial  
 108  
 
 
 
Figure 5-3: Increased neurite swellings within SPG15 and SPG48 telencephalic neurons. 
(A) Representative images of telencephalic neurons with axonal swellings labeled with 
arrowheads. Scale bar: 20µm. (B) Quantification revealed a significant increase in axonal 
swellings in patient-derived neurons compared to control neurons. *P< 0.05 compared to iWT-1. 
#P< 0.05 compared to iWT-sibling cells.  
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Figure 5-4: SPG15 and SPG48 neurons have altered mitochondrial morphology. (A) 
Immunofluorescence images of mitochondria within neurites taken in live, week 10 telencephalic 
glutamatergic neurons that were stained with MitoTracker CMXRos. Scale bar: 20µm. (B) 
Average mitochondrial length, calculated by measuring the longest axis of each mitochondrion. 
(C) Average aspect ratio, calculated by dividing the major axis by the minor axis for each 
mitochondrion. (D) Average number of mitochondria per 1µm neurite. (E) Average linear 
mitochondrial density, calculated by dividing the total mitochondrial area by the neurite length. 
(F) Mitochondrial staining in week 10 mDA neuron cultures. (G) Mitochondrial length, (H) 
mitochondrial aspect ratio, (I) mitochondria per 1µm neurite, and (J) linear mitochondrial 
density. *P<0.05, **P<0.01, ***P<0.001 versus iWT-1. 
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morphology. While the mitochondrial length was only altered in the SPG15 neurons (Fig. 5-4G), 
the number of number and density of mitochondria along neurites was significantly reduced in 
both SPG15 and SPG48 (Fig. 5-4I&J). There was also an increase in mitochondrial size within 
the cell bodies of SPG15 and SPG48 mDA neurons (Supp. Fig. 5-4). This resembles findings in 
PINK1-/- mouse fibroblasts, cortical neurons, and ES cells were found to have enlarged 
mitochondrial size via EM analysis [237]. These results suggest that spastizin and AP5Z1 play a 
role in mitochondrial shape and distribution in neurons.  
 
Next, we sought to examine whether mitochondrial health was affected in SPG15 neurons. The 
cells were incubated with the fluorescent dye TMRM, which binds to mitochondria based on the 
membrane potential (Δψm) [238]. This revealed a significant reduction in TMRM fluorescence in 
SPG15 telencephalic glutamatergic neurons (Fig. 5-5A&B). The TMRM signal was dependent 
on Δψm , as the uncoupler FCCP reduced TMRM fluorescence, and SPG15 neurons had a 
significantly greater decrease (Fig. 5-5C). This data reveals that the loss of spastizin has a 
negative effect on mitochondrial membrane potential. 
 
Considering that alterations in mitochondrial membrane potential can result in the 
release of cytochrome C and apoptosis [239], we then examined apoptosis in telencephalic and 
mDA neurons using caspase 3/7 activity as a readout. Week 10 SPG48 telencephalic neurons 
and SPG15 mDA neurons had significantly increased caspase 3/7 activity (Fig. 5-6A&B).  
 
5.4.4 Inhibition of mitochondrial fission partially rescues SPG15 telencephalic neuron 
defects. 
The reduced size of mitochondria and increased apoptosis in SPG15 and SPG48 
neurons suggest that these neurons may have increased mitochondrial fission. To confirm that 
increased mitochondrial fission is involved in the pathogenesis of SPG15 and SPG48, we tested  
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Figure 5-5: Reduced mitochondrial membrane potential in SPG15 neurons. (A) 
Representative images of control and SPG15 neurons stained with TMRM. (B) Quantification of 
average pixel fluorescence intensity of TMRM before and after FCCP treatment. (C) Change in 
TMRM fluorescence intensity shown by ΔF which represents the levels of mitochondrial 
membrane potential. FCCP was added at 300 sec to decrease mitochondrial membrane 
potential. Data represents mean ± SEM from at least 50 cells from 3 independent experiments. 
**P<0.01. 
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Figure 5-6: SPG15 and SPG48 neurons have increased caspase 3/7 activity. (A) Caspase 
3/7 activity in week 10 telencephalic neuron cultures. (B) Caspase 3/7 activity in week 10 mDA 
neuron cultures. Data were presented as mean ± SEM, n=6. **P<0.01. 
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the effect of mdivi-1 (mitochondrial division inhibitor 1) in SPG15 and SPG48 neurons. This drug 
is an inhibitor of the large GTPase dynamin-related protein 1 (Drp1), which mediates 
mitochondrial fission [240]. The concentration of 10µM mdivi-1 was chosen as it was previously 
reported to be effective in rescuing mitochondrial defects in PINK1 mutant dopaminergic 
neurons without inducing donut-shaped mitochondria [241]. Telencephalic glutamatergic 
neurons were plated onto coverslips and 24 hr later, were treated with 10µM mdivi-1 or vehicle 
for 48 hr. Next, the mitochondrial morphology and neurite outgrowth was examined. Treatment 
with mdivi-1 significantly increased the number of mitochondria per 1µm in neurites for both 
SPG15 and SPG48 neurons, while there was no effect on control neurons (Fig. 5-7A&B). While 
mdivi-1 reduced the linear density of mitochondria in control neurons, it significantly increased 
linear density in SPG15 and SPG48 neurons (Fig. 5-7C). The average mitochondrial length was 
also rescued in SPG15 neurons, with a trend of improvement in SPG48 neurons (Fig. 5-7D). 
Lastly, the aspect ratio was also increased in SPG15 neurons, and there was a non-significant 
trend towards an increase in SPG48 neurons (Fig. 5-7E). These results suggest that mdivi-1 
may improve the health of mitochondria, increasing their transport into neurites, since transport 
is reduced when mitochondria become damaged [146].   
When neurite outgrowth was analyzed following 48 hr mdivi-1 treatment, there was a 
significant increase in axon and primary neurite length in SPG15 neurons (Fig, 5-8A-C). In 
contrast, control neurons had a significant reduction in axon length and a non-significant trend 
towards reduced primary neurite length. The total length of neurites per cell was unchanged in 
control neurons, but was significantly increased in the SPG15 telencephalic glutamatergic 
neurons (Fig. 5-8D). Lastly, when we looked at the effect of mdivi-1 on caspase 3/7 activity, 
there was no effect on control neurons, but a significant reduction in SPG15 neurons (Fig. 5-
8E). These findings suggest that restoring mitochondrial normal morphology can rescue the 
disease-specific phenotypes in SPG15 and SPG48 neurons.  
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Figure 5-7: Inhibition of mitochondrial fission rescues mitochondrial morphology. (A) 
Representative image of axonal mitochondria stained with MitoTracker CMXRos treated with 
vehicle or 10µM Mdivi-1 for 48 hr. (B) Quantification of the number of mitochondria per 1µm 
axon. (C) Linear mitochondrial density. (C) Average mitochondrial length along axons. (D) 
Average mitochondrial aspect ratio. Data represented as mean ± SEM from at least 20 axon 
segments from 3 independent experiments. . *P<0.05, **P<0.01, ***P<0.001 versus iWT-Sib 
DMSO treated. #P<0.05, ##P<0.01, ###P<0.001 versus iWT-Sib Mdivi-1 treated. 
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Figure 5-8: Inhibition of mitochondrial fusion improves neurite outgrowth in SPG15 
forebrain cells. (A) Representative images of telencephalic neurons following 48 hr treatment 
with vehicle or 10µM Mdivi-1. Scale bar: 20µM. (B) Average length of the longest neurite. (C) 
Average length of primary neurites per cell. (D) Total length of all neurites per cell. Data 
presented as mean ± SEM from at least 30 cells from 3 independent experiments. (E) Caspase 
3/7 activity following 72 hr treatment with vehicle or Mdivi-1. *P<0.05, ***P<0.001 versus iWT-1 
DMSO treated. ##P<0.01 versus iWT-Sib Mdivi-1 treated. 
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5.5 Discussion 
Here, we successfully established human neuronal models for SPG15 and SPG48 by 
generating patient-specific iPSCs and differentiated these stem cells into different neuronal 
subtypes. Our results showed that the lack of spastizin or AP5Z1 results in cell-type specific 
defects in telencephalic and mDA neurons, but not spinal neurons. Our data also implicates 
dysfunctional mitochondria in SPG15 and SPG48. There was a significant reduction in 
mitochondrial length and density within neurites, and SPG15 neurons had reduced Δψm. In 
addition, there was increased caspase 3/7 activity in SPG15 and SPG48 neurons in long-term 
cultures. Treatment with the Drp1 inhibitor mdivi-1 rescued mitochondrial morphology defects, 
and partially rescued neurite outgrowth defects in SPG15 cells. Mdivi-1 also reduced caspase 
3/7 activity, suggesting that targeting mitochondria may be beneficial in the future.  
 
5.5.1 Proper neurite outgrowth requires spastizin and AP5Z1: 
Both SPG15 and SPG48 telencephalic neurons had a dramatic reduction in axon length, 
primary neurite length, and number of primary neurites, while there was a more dramatic 
reduction in neurite outgrowth parameters for SPG48 mDA neurons. This matches the clinical 
findings from the SPG48 patient, who has parkinsonism, while the SPG15 patient does not. 
Early neurite outgrowth defects appears to be a common finding among several HSP subtypes, 
including SPG3A [24], SPG4 [62], and SPG11 [38]. The previous finding that both patient-
specific SPG11 iPSC-derived cortical neurons, and spatacsin knockdown neurons have 
reduced axonal outgrowth in vitro, is interesting, as this HSP subtype is nearly clinically identical 
to SPG15 and SPG48. The thin corpus callosum that is often associated with SPG15 and 
SPG48 is thought to be a developmental defect [14], which may arise from the reduced ability of 
corticofugal axons to reach their target, as shown in our in vitro results. 
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5.5.2 Abnormal mitochondrial dynamics in SPG15 and SPG48 neurons: 
Spastizin was previously shown to partially colocalize with mitochondria [82]. We found that 
SPG15 and SPG48 cells had smaller, fragmented mitochondria with lower density along 
neurites. This suggests that spastizin levels may affect mitochondrial fission/fusion balance. 
While it is possible that spastizin does so directly, it is most likely a result of the reduced 
autophagic flux that occurs when spastizin levels are reduced [93, 97, 242]. It was recently 
shown that spastizin is important for autophagic lysosome reformation, a process that generates 
new free lysosomes [93]. Perhaps a deficiency in free lysosomes that occurs when spastizin is 
reduced, results in the accumulation of autophagic material, including damaged mitochondria. 
We observed a decrease in mitochondrial Δψm and increased mitochondrial fragmentation, 
which resembles findings from familial forms of Parkinson’s disease, where PTEN-induced 
kinase 1 (PINK1) or parkin are mutated [241]. The two Parkinson’s disease associated proteins, 
PINK1 and parkin are directly involved in mitophagy. Parkin is targeted to damaged 
mitochondria, such as those with low membrane potential, in a PINK-1 dependent manner [243]. 
Parkin then ubiquitinates mitochondrial proteins, allowing adaptor proteins, such as p62 to bind 
and trigger phagophore formation, leading to degradation [244]. The fragmented mitochondria 
observed in SPG15 and SPG48 neurons may be awaiting degradation via mitophagy, as 
mitochondrial fission has been shown to precede mitophagy [245, 246]. In the future, it will be 
interesting to further investigate the connection between spastizin, PINK1, and parkin. 
 
5.5.3 Mdivi-1 rescues disease-related phenotypes in SPG15 neurons: 
The finding that the Drp1 inhibitor, mdivi-1, can partially rescue SPG15 telencephalic 
neurons suggests that mitochondrial fission is involved in the pathogenesis of SPG15. Our 
results are similar to a study where mitochondrial defects in mutant PINK1 N27 neuronal cells 
could be rescued by the application of 10µM mdivi-1 [241]. Mdivi-1 does not affect mitochondrial 
fusion, therefore the inhibition of fission would favor increased mitochondrial fusion, which we 
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can detect by the presence of longer mitochondria along neurites. Regulation of mitochondrial 
fission and fusion is important during apoptosis [247]. Previous work has shown that 
mitochondrial fusion is anti-apoptotic [248-250], while fission can be pro-apoptotic [240]. During 
apoptosis, Drp1 accumulates on mitochondria and increases the rate of division and 
fragmentation [240]. Inhibition of Drp1 with mdivi-1 can reduce cytochrome-c release following 
apoptosis stimulation. Our results showed that mdivi-1 can rescue neurite outgrowth deficits and 
reduce subsequent caspase-3/7 activity in SPG15 telencephalic neurons. In the future it will be 
interesting to determine the detailed mechanisms by which mdivi-1 improves neurite outgrowth 
and rescues the axonal degeneration.  
 
In summary, we have developed a novel model of SPG15 and SPG48 using hPSCs. 
This model was successful in identifying disease-specific phenotypes that may prove useful for 
drug-screening studies in the future. In addition, abnormalities to mitochondria are a common 
observation in SPG15 and SPG48. These phenotypes were partially rescued through the 
inhibition of Drp1, suggesting that targeting mitochondrial dynamics may be a potential 
therapeutic avenue in the future. 
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5.6 Supplemental Figures 
 
 
 
Supplemental Figure 5-1: Generation and characterization of SPG15 and SPG48 iPSC 
lines. (A) Representative phase contrast images of SPG15 and unaffected sibling (iWT-1) iPSC 
lines. Scale bar: 200µm. (B) Sanger sequencing identified compound heterozygous mutations in 
the fyve-cent gene in the SPG15 patient line. One mutation is located at the splice acceptor site 
of intron 14 (c.2554-1 G>A) resulting in the skipping of exon 15, and the other is a nonsense 
mutation in exon 19 (c.3417_3418insTA; p. Lys1140X) which results in the truncation of the 
protein. (C) Sequencing of the SPG48 iPSCs revealed a homozygous C>T nucleotide 
substitution (c.1732 C>T) resulting in a premature stop codon in exon 15 of the AP5Z1 gene. 
(D) SPG15 and SPG48-derived iPSC colonies display typical ESC-like morphology. Scale bar: 
100µm. (E) All examined lines stained positive for the pluripotency markers Nanog, SSEA-4, 
and Tra-1-60.  Scale bar: 100µm.  
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Supplemental Figure 5-2: Reduced spastizin and AP5Z1 expression in SPG15 and SPG48 
forebrain neurons respectively. (A) qRT-PCR analysis of spastizin expression in week 15 
telencephalic glutamatergic neuron cultures. (B) AP5Z1 expression in control and iSPG15 week 
15 telencephalic glutamatergic neuron cultures. Data were presented as mean ± SD , n=6. 
*P<0.05 
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Supplementary Figure 5-3: Reduced telencephalic glutamatergic neuron neurite 
outgrowth from additional clones. (A) Immunofluorescence images of day 33 forebrain 
neurons taken 72 hr after plating. (B) Quantification of the longest neurite. (C) Mean length of 
primary neurites per cell. (D) Number of primary neurite per cell. (D) Number of branches per 
cell. Data presented as mean ± SEM. *P<0.05, **P<0.01.
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Supplemental Figure 5-4: Increased mitochondrial size within cell bodies from mDA 
enriched cultures. (A) Representative TEM images of neurons within mDA cultures. (B) 
Quantification of the mitochondrial area within mDA cultures. Data represented as mean ± SEM 
from n ≥ 20 cells. *P<0.05, **P<0.01. 
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6. Chapter 6 
Significance, Challenges, and Future Directions 
Here, we have shown that multiple forms of HSP can be studied using patient iPSC-
derived neurons. Many phenotypes observed in adult patients were recapitulated in iPSC-
derived neurons, suggesting that cellular abnormalities may be present prior to clinical 
diagnosis. We observed length-dependent axonal swellings in SPG4 neurons, and neurite 
outgrowth abnormalities in SPG3A neurons (Fig. 6-1). These phenotypes were rescued 
following treatment with the microtubule-targeting drug vinblastine, linking alterations to 
microtubule dynamics in these forms of autosomal dominant HSP. In addition, the role of 
spastin in axonal transport was confirmed in human neurons, matching previous findings in 
mice. A novel role of atlastin-1 in fast axonal transport of mitochondria was identified, 
suggesting a common deficit in SPG3A and SPG4.   
 We next investigated SPG15 and SPG48, two autosomal recessive forms of HSP 
associated with juvenile parkinsonism. This revealed cell-type specific deficits in telencephalic 
glutamatergic and mDA neurons, two neuronal subtypes affected in patients (Fig. 6-2). 
Importantly, spinal neurons, which are unaffected in patients, showed no abnormalities. Our 
analysis also revealed a previously unrecognized role of mitochondria in SPG15 and SPG48. 
Cells lacking spastizin or AP5Z1 had reduced mitochondrial size and decreased density within 
neurites. In addition, mitochondria were less polarized, showing reduced Δψm. Treatment with 
the Drp1 inhibitor, mdivi-1, rescued mitochondrial morphology abnormalities in SPG15 neurons. 
Interestingly, mdivi-1 partially rescued neurite outgrowth defects in SPG15 cells, suggesting that 
an imbalance of mitochondrial fission/fusion may result in pathogenic changes. 
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Figure 6-1: Summary of major phenotypes observed in SPG4 and SPG3A iPSC-derived 
neurons. The phenotypes that were rescued by vinblastine are also shown. 
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Figure 6-2: Summary of major phenotypes observed in SPG4 and SPG3A iPSC-derived 
neurons. The phenotypes rescued by inhibition of mitochondrial fission are also shown.
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6.1 Establishing models of HSP 
One of the factors that have limited HSP research is the generation of animal models 
that accurately recapitulate disease phenotypes. To date, out of the 71 HSP-linked loci, only 13 
have been studied in zebrafish or drosophila, while 12 have been examined in mice. This is due 
to both fact that the speed with which new HSP gene are identified has outpaced researchers 
ability to generate animal models and differences in expression of HSP genes between human 
and animal models [18].  The ability to examine the role of HSP genes in human neurons with 
stem cell technology allows researchers to overcome the lack of animal models. The availability 
of stem cell models for every HSP subtype is available should be a reality in the near future. 
This would greatly enhance the understanding of the pathways necessary for maintenance of 
long axons. One of the roadblocks to this is the limited availability of HSP patient fibroblasts, 
making large cohorts of cell lines difficult to employ. The best way to get around this limitation 
would be to use newer gene targeting techniques, such as the TALEN [251] or CRISPR/Cas 
systems [252], to introduce mutations identified in patients to every HSP gene in a control cell 
line, such as H9 hESCs. If all of the lines were generated from the same original control line, 
they would be in effect isogenic, dramatically reducing the potential variability between control 
and mutant lines that occurs when comparing lines from individuals with different genetic 
backgrounds. Stem cell based models also allow the identification of events that precede 
disease onset, since early born neurons are examined [253]. This is particularly valuable when 
attempting to identify therapeutic compounds that can prevent disease progression. If a 
pathogenic event can be detected prior to neurodegeneration, studies can be designed to test 
for the inhibition of that event. Therapies that prevent disease onset and progression will be 
more and more valuable as genetic sequencing becomes cheaper and more widespread. 
Children who are at risk of inheriting HSP can be sequenced at an early age, allowing 
preventative measures to be taken.  
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 It would also be informative to transplant HSP iPSC-derived neurons into animals to test 
whether or not the phenotypes observed in vitro are seen in vivo. The conditions that cells are 
exposed to in vitro are much harsher than those in vivo, resulting in increased oxidative stress, 
potentially leading to misleading phenotypes [254]. Transplantation of cells would also allow 
testing therapeutic agents effect in a more physiologically relevant environment. This would also 
allow neurons to be examined after longer periods of time in vivo than would be possible in vitro. 
With current culturing techniques stem cell-derived neurons do not survive in vitro indefinitely, 
but transplanted neurons have been shown to survive at least 2 years in vivo [255].  
 
6.2 Overcoming cellular heterogeneity 
 One of the difficulties when working with stem cell-derived neural cultures is the 
heterogeneity of cells generated from directed differentiation protocols. Following neural 
differentiation, many studies will use immunohistochemistry or transcriptional profiling to 
determine whether the cell-type of interest is present in the culture, and to what extent. 
However, often studies fail to fully characterize the other cell-types that are present in the 
culture, providing a potential significant source of variation, as a number of neurodegenerative 
diseases result from non-cell autonomous mechanisms. If a culture only contains a small 
percentage of neurons of interest, this could make it difficult to observe subtle phenotypes, 
particularly if the other cells in the culture are unaffected in the disease, or perhaps the 
unaffected cells may support the affected cells by providing metabolic or intracellular signals. 
One way to get around this is to use a purification technique, such as fluorescence-activated 
cell sorting (FACS), to obtain pure populations of the neuronal subtype of interest. This however 
requires a specific surface marker for the particular neuronal subtype, which is not currently 
available for all clinically relevant cell populations, such as CSMNs. This strategy has worked 
well for studies examining diseases affecting spinal motor neurons [256] or mDA neurons [257], 
as specific markers are available to purify these cells. In the case of HSP, using generic 
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telencephalic glutamatergic neurons is appropriate for some autosomal recessive subtypes, 
such as SPG15 and SPG48, where widespread abnormalities are seen in neurons whose axons 
pass the corpus callosum. For autosomal pure HSP subtypes, such as SPG3A and SPG4, the 
ability to purify neurons with transcriptional or proteomic profiles that match deep layer neurons, 
particularly CSMNs, will enhance our ability to identify why these neurons are specifically 
susceptible to degeneration. 
 
6.3 Examining the physiological role of HSP proteins 
 To date, almost no work has been done to examine the physiological importance of HSP 
proteins in neurons. The majority of studies have looked at morphological defects of cells when 
levels of HSP proteins are perturbed. This lack of information needs to be resolved, as a 
number of HSP proteins are involved in pathways that have direct effect on synaptic 
transmission and electrophysiology.  
In addition, mitochondria play a crucial role to presynaptic function, as these regions rely 
on high levels of ATP to maintain ionic gradients and membrane potential, and to reload 
synaptic vesicles [258, 259]. Mitochondria within presynaptic terminals also serve to sequester 
cytosolic Ca2+ during neurotransmission [260]. The involvement of mitochondrial health and 
transport in multiple forms of HSP suggest it would be interesting to examine whether 
electrophysiological properties are altered in these HSP neurons. 
 
6.4 Identifying mechanism for cell-type specific susceptibility in HSP. 
 As mentioned earlier, understanding why particular subpopulations of neuron 
degenerate when ubiquitously expressed proteins are lost, such as spastin or atlastin-1, is very 
important. We have attempted to use our iPSC-based SPG4 and SPG3A models to shed light 
on this question. We previously observed that SPG4 and SPG3A telencephalic glutamatergic 
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neuron enriched cultures, but not spinal neuron cultures, had increased axonal swellings or 
decreased neurite outgrowth (Fig. 6-3). We chose to use RNA-sequencing analysis to identify 
genes and pathways that were specifically altered in forebrain HSP neurons. RNA was collected 
from week 7 wild-type, SPG4, and SPG3A forebrain and spinal neuron cultures, and libraries 
were prepared using Illumina’s specifications for polyA-plus stranded reactions. Samples were 
analyzed using an Illumina HiSeq 2000 sequencer. With the assistance of Dr. Michael Duff, the 
reads were mapped to the human hg19 genome using TopHat2 [261] and Bowtie2 [262]. 
Expression quantification in fragments per kilobase gene model per million base pairs (FPKM) 
was performed using Cuffdiff [263]. A threshold of genes with a minimum FPKM>1 and a 
maximum FPKM>10 and absolute value of log-fold change is > 1 (so gene fpkm either 
increased or reduced by a factor of at least 2) were chosen for further analysis. The number of 
genes that differed between control and SPG4 or SPG3A are shown in Fig. 6-4. In order to 
exclude changes that also occurred in spinal neurons, those genes were removed from the list. 
This resulted in 956 genes that were reduced specifically in SPG3A forebrain cells, and 227 
genes that were increased. For the SPG4 cells, 1643 genes were specifically reduced, and 475 
genes were increased. Because SPG3A and SPG4 are related, we chose to examine the 
commonly altered genes between these two groups. There were 695 genes that were 
decreased in both SPG3A and SPG4 forebrain cells compared to controls, and only 73 that 
were increased. 
 Next, the list of commonly altered genes was examined using gene ontology (GO) 
analysis using DAVID (http://david.abcc.ncifcrf.gov/). This revealed a number of GO terms that 
were enriched in these lists (Table 6-1). A number of the GO terms that were enriched in the 
gene lists make sense based on the roles of spastin and atlastin-1. The GO term that was most 
enriched in the genes that were downregulated in SPG3A and SPG4 telencephalic 
glutamatergic neurons was “regulation of cell morphogenesis.” In the SPG3A list of genes, there 
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were enriched GO terms related to cellular projections and endocytosis. The genes that were 
decreased in SPG4 were enriched for GO terms related to cytoskeleton and lipid regulation. Our 
next step is to validate expression changes using qPCR for a subset of the clinically relevant 
genes that were altered in SPG3A and SPG4. We have chosen to focus on genes involved in 
ER stress, as it has been found to be an early pathogenic change in several neurodegenerative 
disorders [256, 264].  
 
6.5 Implications for other neurodegenerative disorders 
 One of the aspects that makes studying HSP relevant to neurodegenerative disorders as 
a whole is the extensive genetic characterization of the different HSP subtypes (Table 1-1). The 
fact that mutations to 71 genes and counting all lead to the common phenotype of degeneration 
of the longest axons can provide insight into the pathways that are needed for axonal 
maintenance in general and in other neurodegenerative disorders. An understanding of the 
genes and pathways that result in HSP is also beneficial to understanding the mechanisms of 
other neurodegenerative disorders, as it seems likely that there are pathways affected in 
multiple diseases, such as axonal transport (Parkinson’s , Alzheimer’s, ALS, Huntington’s, HSP 
[265]), ER stress (Huntington’s disease [266], ALS [267], SBMA [264]), RNA processing (SMA 
[268], ALS [269]), mitochondrial quality control (Parkinson’s [270], Alzheimer’s [271], ALS [272], 
HSP [1]). A recent study performed exome sequencing on 55 families with autosomal recessive 
HSP, but lacked a genetic diagnosis [18]. They identified 18 unknown HSP genes, and also 
performing pathway analysis using protein interaction databases to show that HSP genes are 
more highly connected within the network than expected by chance. There was also a 
significant overlap between HSP genes and those implicated in Alzheimer’s disease, ALS, and 
Parkinson’s disease. This finding suggests that common pathways are disrupted in different 
neurodegenerative disorders, yet different cell types are affected in each. This question of why 
particular neuronal subtypes are affected in different neurodegenerative diseases has interested 
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researchers for decades. Perhaps in the future, instead of studying each disease separately, 
combining analysis through bioinformatic approaches of multiple disorders at once may yield 
new insights. 
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Figure 6-3: Examination of spastin isoform levels between forebrain and spinal neuron 
cultures. (A) Western blot examining the levels of different spastin isoforms between week 11 
forebrain and spinal motor neuron cultures. (B) Quantification of the larger M1 spastin isoform, 
normalized to actin levels. (C) Quantification of the smaller, cytoplasmic M87 spastin isoform. 
Data represented as mean ± SD. *P<0.05. (D) Schematic diagram of approach used in part F. 
(E) Schematic diagram of the approach used in part G. (F) Quantification of axonal swellings in 
week 8 control and SPG4 neurons. (G) Quantification of week 8 neurite outgrowth  in forebrain 
and spinal neuron cultures 48 hr after plating. Data presented as mean ± SEM. *P<0.05.
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Figure 6-4: RNA-seq analysis of SPG3A and SPG4 iPSC-derived neurons. Venn diagrams 
depicting the number of genes differentially expressed between groups, either two-fold 
decreased or increased. Genes that were differentially expressed in spinal MN and forebrain 
cells were excluded from the forebrain list, to yield forebrain-specific differentially expressed 
genes. On the right, forebrain-specific differentially expressed genes from SPG3A and SPG4 
cells were compared, to identify genes commonly altered genes. 
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6.6 Developing therapeutics for HSP 
 Here, we used iPSC-models of four HSP subtypes to test the effects of several 
therapeutic compounds. We were able show that low doses of the microtubule-targeting drug 
vinblastine rescues the axonal swelling phenotype in SPG4 cells, and the neurite outgrowth 
phenotype in SPG3A. The finding that targeting microtubule dynamics is beneficial to human 
SPG4 neurons matches results from primary neurons of a SPAST-/- mouse [167]. In that study, 
only mice completely lacking spastin expression showed any phenotype, while SPG4 patients 
had roughly 50% spastin expression. This suggests that mice may have a compensatory 
mechanism that protects them from axonal abnormalities when spastin levels are reduced by 
50%. Several potential mechanisms could explain this. First, there is a dramatic difference in the 
length of axons between humans and mice. Our results would suggest that differences in axon 
length is responsible, at least in vitro, as our cultured SPG4 cells showed length-dependent 
axonal swellings in cells that were roughly the same size as the primary cultured mouse cells, 
yet the heterozygous mouse neurons did not have swellings. Secondly, expression differences 
between spastin isoforms may partially explain the species differences in the effect of reduced 
spastin expression. Previous work in mice found that the smaller M87 spastin is the major 
isoform present in all nervous system tissue, and that the M1 isoform is only detected in the 
spinal cord [61]. We however detect significant amounts M1-ΔEx4 spastin in both telencephalic 
and spinal neuron cultures (Fig. 6-3). We also see a small amount of full-length M1 spastin in 
both types of neurons, with higher levels in the telencephalic glutamatergic cultures. This result 
suggests that there are differences in spastin isoform abundance between human and mouse 
neurons, and perhaps human neurons are more sensitive to a decrease in M1 spastin levels, so 
when one copy of the SPAST gene is disrupted, axon degeneration occurs. A third possibility 
that may explain the species difference in spastin dosage tolerance may be that other 
microtubule-severing enzymes, such as katanin or fidgetin, can compensate for the 50% loss of 
spastin in mice, but not in human neurons. The differences in katanin or fidgetin expression 
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between human and rodent brain regions have not been compared, yet this may explain why 
mice are unaffected when spastin expression is reduced by 50%, but this same reduction leads 
to axon degeneration in humans.  
The beneficial effect of targeting microtubule dynamics in SPG4 was confirmed in 
olfactory neurosphere-derived cells from SPG4 patients [273]. Here, researchers found that very 
low doses of four microtubule-targeting drugs, vinblastine, taxol, epothilone, and noscapine, 
could rescue peroxisome trafficking deficit in SPG4 cells.  Because the concentration of drugs 
used was roughly 100-1000 fold lower than the concentrations used to block mitosis and trigger 
apoptosis in cancer cells [274], the authors suggest that these doses might well-tolerated by 
patients. All four of these drugs have already passed Phase I clinical trials, suggesting they 
could be candidates for repurposing. Vinblastine would not likely be helpful to patients, as it 
does not cross the blood-brain barrier, but epothilone-D does [275], making it a potential 
candidate for testing the side effects of chronic doses at low concentrations.  
We also found that treatment with mdivi-1, an inhibitor of mitochondrial fission, rescued 
mitochondrial morphology, neurite outgrowth, and caspase activation in SPG15 neurons. This 
compound has been found to prevent neurotoxicity and increase dopamine release in two  
mouse models of Parkinson’s disease, PINK1-/- mice and 1-methyl-4-phenyl-1,2,3,6 
tetrahydropyridine (MPTP) mice [276]. They showed that mdivi-1 could penetrate the blood-
brain barrier, and intraperitoneal injection once a day for 5 days prevented nigrostriatal 
dopaminergic neuron loss that occurs following MPTP injection. More work is needed to 
evaluate whether targeting mitochondrial dynamics is a viable strategy for treating 
neurodegenerative disorders. Although it has been previously established that altering 
mitochondrial dynamics in “healthy” cells is detrimental, as Drp1 knockout (loss of mitochondrial 
fission) or OPA1 knockout (reduction in mitochondrial fusion) are embryonic lethal [277-280], 
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more work on the side effects of mdivi-1 treatment are needed. In two studies in mice, there 
were no adverse effects to short term mdivi-1 treatment for up to a week [276, 281].    
 While the studies presented here took advantage of stem cell-derived neurons to test for 
therapeutic compounds, it was on a very small scale. In the future, these systems can be used 
to screen many more compounds to identify those with the greatest effect and lowest toxicity. 
To accomplish this, high content screening systems can be employed, such as the PerkinElmer 
Opera automated confocal microscope. For SPG3A, SPG15, and SPG48, the measurement of 
neurite outgrowth parameters can be automatically quantified using existing software [282]. The 
automated identification of axonal swellings is a little more difficult because no software is 
currently available to do so. Our group is collaborating with researchers at the Sanford-Burnham 
Medical Research Institute to develop methods for quantifying axonal swellings from high-
content images. This would allow large-scale screening of chemical libraries for compounds that 
can reduce the number of swellings, while not affecting neuron survival or neurite outgrowth. 
 
6.7 Conclusions 
 Here, we have generated novel models of four HSP subtypes using stem cell 
technology. This has allowed the identification of novel phenotypes, including altered axonal 
transport in SPG4 and SPG3A, and impaired mitochondrial health in SPG15 and SPG48. These 
iPSC-based models were used to show the beneficial effects of vinblastine and mdivi-1 at 
rescuing disease phenotypes. This confirmed that targeting microtubule dynamics in SPG3A 
and SPG4 deserves further investigation in HSP patients, as currently no therapies are 
available for this neurodegenerative disease. The conclusion that inhibiting mitochondrial 
division rescues neurite outgrowth defects in SGP15 neurons suggests a novel therapeutic 
approach for this severe form of HSP. There remain many questions that need to be answered 
before the mechanisms that lead to axonal degeneration in SPG3A, SPG4, SPG15, and SPG48 
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are fully understood, however the tools and findings reported here should help answer some of 
those questions in the future. 
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